Enrico Capobianco Ph.D.
Lead Scientist, Center for Computational Science, University of Miami
Enrico Capobianco is an expert of complex systems with a wide experience at an international scale. He has explored the field of Biomedicine in multiple areas. He works as since 2012 a Lead Scientist at the Center for Computational Science, University of Miami, and collaborates with the Miller School of Medicine (Immunology, Dermatology, Neurology), the Bascom Palmer Eye Institute and the Sylvester Comprehensive Cancer Center.
He studied quantitative disciplines at LSE, London (1991-92), Northwestern University (1992) and UC Berkeley (Statistics, 1992-92; Mathematical Sciences Research Institute, 2003), Stanford (1994-1998, Computer Science, AI Lab ), Niels Bohr Institute and Danish Technical University (1999, NATO-CNR Fellow, Neurocomputing), CWI – Center for Mathematics and Computer Science, Amsterdam (2001-2001, ERCIM Fellow, Stochastics), Boston University (2004-2005, Biomedical Engineering), Serono, Evry (2005, Head of Methods), CRS4, Sardinia, Polaris Science & Tech Park (2006-11, Head of Quantitative Systems Biology Group, National Research Council, Institute of Clinical Physiology, Pisa (2012-2015, Founding PI of LISM – Laboratory of Integrative Systems Medicine; 2016-2017, Coordinator in Big Data in Health) .
He got professorships from CAS in China (2011, Shanghai) and Fiocruz Foundation (Rio, Brazil 2008-2010, Program, Capes – FIOCRUZ). His activities include includes multiple participation in academic programs at SAMSI, IMA, MSRI and IPAM Institutes in US, and visiting appointments at the International Centre for Theoretical Physics (Condensed Matter, 2003,Trieste), and at the Institut des Hautes Études Scientifiques (IHES) (Paris, 2010).
Enrico has been contributing to the growth of the field of Systems Medicine, especially leading Network Science towards both methodological advances and cancer applications. He is now focused on Precision Medicine, and particularly active in Computational Imaging and Big Data.
Beth Anne Baber Ph.D, MBA.
Co-Founder and CEO, The Nicholas Conor Institute
While Beth Anne was a cancer geneticist at the Salk Institute, her son, Conor, was diagnosed with neuroblastoma. She and her husband, a faculty member at The Scripps Research Institute, applied an evidence-base approach toward their son’s cancer care. Today, Conor is a healthy 13 year-old. Beth Anne co-founded The Nicholas Conor Institute, a non-profit aimed at advancing promising discoveries through the development pipeline. Armed with a background in research and business, she has become an effective patient advocate for pediatric cancers and rare diseases. She was instrumental in the establishment of $126M bi-partisan pediatric medical research initiative and generated funding for cancers of children, adolescents and young adults through the Department of Defense. In addition to being an advocate member of the Stand Up to Cancer Pediatric Cancers Dream Team, Beth Anne provided a voice for children and innovative patient engagement platforms during the development of the Precision Medicine and Cancer Moonshot Initiatives.
Brad Perkins, MD, MBA
Chief Medical Officer, Human Longevity
Dr. Perkins is a visionary physician, scientist, and executive who is responsible for leading all clinical and therapeutic operations at the HLI. This includes collecting and utilizing phenotype data, development of the consumer clinics business, and guiding stem cell therapeutics.
Prior to joining HLI, Dr. Perkins was Executive Vice President for Strategy and Innovation, and Chief Transformation Officer at Vanguard Health Systems, a large multi-state, for-profit, integrated health services provider with nearly 46,000 employees. He helped transform Vanguard from a traditional fee for service healthcare model, to a fee for value, “population health” model. Some of his innovative solutions there included: establishing Accountable Care Organizations to improve primary care, implementing an award winning tele-radiology program, and starting a $167 million venture capital fund to support Vanguard’s transformation programs.
Dr. Perkins began his career at the Centers for Disease Control and Prevention (CDC) in 1989 after completing his residency training and chief residency in internal medicine at Baylor College of Medicine. At the CDC he led some of the most important and high profile programs and published more than 120 peer-reviewed publications and book chapters.
He first joined and then led the Meningitis and Special Pathogens Branch where he investigated global bacterial disease epidemics. He co-discovered the bacteria which causes Cat Scratch Diseases and conducted translational research leading to development of several new bacterial meningitis and pneumonia vaccines. In 2001 Dr. Perkins led the investigations into the anthrax attacks in the United States, the largest and highest profile investigation ever conducted by CDC. In 2005 he was appointed CDC’s Chief Strategy and Innovation Officer, a position in which he managed a $11.2 billion budget, and 15,000 employees with offices in more than 50 countries. Working closely with the CDC Director, he built a $2 billion state-of-the-art emergency response capability and positioned the improvement of population health as a focus of the healthcare reform movement within the White House administration at that time.
Dr. Perkins is a member of the RAND Health Board, and he is the chairman of the advisory board for Esther Dyson’s nonprofit, HICCup, sponsor of the “Way to Wellville” community health competition. He received his BA in Microbiology and his MD from the University of Missouri-Columbia, and an MBA from Emory University. He is Board Certified in Internal Medicine.
David Ewing Duncan
Author & CEO Arc Fusion
David Ewing Duncan is an award-winning, best-selling author of nine books published in 21 languages. David is CEO and Curator of Arc Fusion, and a Health Strategist in Residence for IDEO. He is a columnist for the Daily Beast and the chief correspondent for NPR Talk’s Biotech Nation. David writes for The New York Times, Atlantic, Fortune, Wired, National Geographic, Discover, and Outside, among others. He is a former commentator for NPR’s Morning Edition and a special correspondent and producer for ABC’s Nightline and 20/20, a former producer for Discovery Channel, and a correspondent for NOVA’s ScienceNow!. His latest book is When I’m 164: The new science of radical life extension, and what happens if it succeeds (TED books). He also wrote Experimental Man: What One Man’s Body Reveals about His Future, Your Health, and Our Toxic World (Wiley). He is the founding director of the Center of Life Science Policy at UC Berkeley, and is on the faculty at Singularity University. David is finishing his first novel, a biomedical thriller. David’s work has won numerous awards, including Magazine Story of the Year from AAAS, and has been nominated twice for a National Magazine Award. He serves on a committee of the National Academies of Sciences. David lives in San Francisco and is a member of the San Francisco Writers’ Grotto.
Dana Hosseini, MBA
Co-Founder & CEO, ProdermIQ, Inc.
A serial entrepreneur who has managed and co-founded a number of genomics-based companies including, ProdermIQ, Iceland Genomics and DiThera. Mr. Hosseini’s skills in international medical device/diagnostic sales and market were developed at Abbott Laboratories, Ortho Clinical Diagnostics (Johnson & Johnson) and Sequenom where he held executive and management positions in business development, sales and marketing functions. He has 25+ years of extensive experience working with global biotech, pharmaceutical companies and healthcare providers. He received both his B.Sc. and MBA from the University of British Columbia.
Deputy Vice President of Policy & Research at PhRMA
Gretta Stone is deputy vice president of policy & research at PhRMA, where she works to communicate the positive contribution of biopharmaceutical companies and their products. She manages a range of issues related to the R&D process, FDA regulation, the value of medicines, and personalized medicine. Gretta has authored many PhRMA reports and publications including the annual Biopharmaceutical Industry Profile, an overview of the sector and a go-to source of data on the industry; the Setbacks and Stepping Stones series on medicines that do not make it to approval but pave the way for progress; and the Decade of Innovation series on advances in the fight against many diseases. In her more than twelve years at PhRMA she has also work extensively on orphan drugs, the biopharmaceutical pipeline, the research ecosystem, the cost of medicines, and marketing and promotion. Gretta also serves on the board of the Society for Women’s Health Research, an organization dedicated to advancing our understanding of the biological differences in disease and advocating to enhance women’s health. Prior to joining PhRMA, Gretta worked in a lab researching language and the brain at Georgetown University, where she received a BS in biology.
Reece Hart, Ph.D.
Chief Technology Office, Genome Medical, Inc.
Reece is Chief Technology Officer at Genome Medical, a nationwide medical practice providing a network of genetic counselors and clinicians who help customers to navigate genetic testing options and to understand genetic results. Genome Medical bridges the gap between genome technology and medical practice by serving both physicians and patients to move us toward a more genome-centered healthcare system. Prior to Genome Medical, he was a Research and Engineering Fellow at Invitae, Director of Engineering at 23andMe, and bioinformatics scientist and manager of research computing at Genentech. He is active leader and contributor to open source/open data efforts to facilitate genomic data sharing, including Global Alliance for Genomic Health, the Variation Modeling Collaboration, and Human Genome Variation Society nomenclature recommendations.
Mary E. Edgerton, M.D, Ph.D.
Associate Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Mary E. Edgerton was born in Austin, Texas and was raised in the Rio Grande Valley. She received a B.S. in Physics with Highest Honors from the University of Texas at Austin. Following this, she was a Marshall Scholar to the United Kingdom where she received a Ph.D. in Biophysics from the University of East Anglia. She completed postdoctoral studies at the Unviersity of California at San Francisco and at the State university of New York at Stony Brook, and then worked for nine years for Exxon and then Mobil Oil Company in their research laboratories. She left the research laboratoires to attend medical school, and obtained her MD. from Medical College of Pennsylvania in Philadelphia. She completed her pathology residency and surgical pathology fellowship at the Hospital of the University of Pennsylvania. She is board certified in Anatomic and Clinical Pathology and was an Assistant Professor of Pathology at Vanderbilt University and an Associate Professor in the Division of Anatomic Pathology at the Moffitt Cancer Center before coming to MD Anderson, where she is currently an Associate Professor with tenure.
Laura Esserman, M.D., M.B.A.
Director of the Carol Franc Buck Breast Care Center, UCSF Medical School, professor of Surgery & Radiology, UCSF, and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center
Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center’s multidisciplinary programs. The program is comprised of 69 faculty members who represent 16 academic specialties and is internationally recognized and well-established with major initiatives in epidemiology, genetics, biology, therapeutics, and clinical cancer care. She is a professor of Surgery & Radiology at UCSF and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.
She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.
She is the Principle Investigator of the I-SPY TRIAL program, a multi-site neoadjuvant clinical trial that has evolved into a model for translational research and innovation in clinical trial design.
Dr. Esserman has recently launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a project designed to follow 400,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care.
Dr. Esserman is nationally and internationally known as a leader in the field of breast cancer and has published over 150 articles in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally. Overall, Dr. Esserman’s research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.
She is a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation, which is studying how the federal government can best support science-based innovation in the process of drug development and regulatory evaluation. In addition, she is a contributing member of a “taskforce” for President Obama’s Council of Advisors on Science and Technology.
Dr. Esserman received her Bachelor’s degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center. After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993. She then joined the faculty at the University of California, San Francisco.
Global Head of Janssen Diagnostics
Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.
In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.
David S. Karow, Ph.D., MD
Chief Medical Imaging Officer, Human Longevity, Inc.
David S. Karow, MD, PhD, Chief Medical Imaging Officer at HLI, is an innovative leader in the medical imaging space who brings more than 10 years of experience in advanced MR Imaging, focused on the development and translation into clinical care of diffusion-based MRI techniques. Dr. Karow is the Chief Radiologist at HLI’s Health Nucleus.
Before joining HLI, Dr. Karow was the Director of Body MRI within the Body Imaging Division and Director of Evening Acute Care Imaging in the Department of Radiology at University of California, San Diego (UC San Diego), where he still serves as Associate Professor, Health Sciences Clinical and Associate Director, Center for Translational Imaging and Precision Medicine. During his time at UC San Diego he, in collaboration with Dr. Anders Dale, PhD, Dr. Nate White, PhD and Dr. Joshua Kuperman, PhD in the Center for MultiModal Imaging and Genetics (CMIG), implemented a new, advanced diffusion method (RSI) that proved beneficial for the detection and in vivo characterization of prostate tumors. He worked to create a standard MRI protocol that is obtained on patients with proven or suspected prostate cancer. The protocol made it possible to obtain standardized, high quality quantitative imaging, which has greatly enhanced the ability to detect, localize and characterize prostate cancer. The work has yielded multiple published papers and led to multiple federal and private research grants on which Dr. Karow was Principal Investigator. Dr. Karow and collaborators continue to investigate using RSI-MRI as a biomarker for cervical cancer radiotherapy treatment response, and are compiling data showing that these techniques may be useful for the screening and staging of cancer across the whole body including breast cancer.
Dr. Karow completed his fellowship in advanced body imaging at University of California, Los Angeles (UC Los Angeles). Prior to entering the Fellowship program at UC Los Angeles, he completed his residency in diagnostic radiology at UC San Diego in the 5-year research residency pathway. His research during residency was recognized with several awards, including the 2011 Elliott C. Lasser Award for Excellence in Research; 2009 American Roentgen Ray Society Executive Council Award; the 2008 RSNA Trainee Research Prize; and his work was also featured on the cover of the September 2010 issue of the journal RADIOLOGY.
Martin Reese, Ph.D.
Founder, President & CEO, Fabric Genomics
Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and UC Berkeley
President & CEO, BIOCOM
Joseph Panetta is President and CEO and a member of the Board of Directors of Biocom, California’s largest and most-experienced leader and advocate for the life science industry. Biocom works on behalf of more than 950 members to drive public policy, build an enviable network of industry leaders, create access to capital development, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs. As President and CEO, he works with an experienced professional staff of 50, with offices located in San Diego, Los Angeles, Tokyo, and Washington, D.C. Together with a 60-member Board of Directors, he leads initiatives that help members produce novel solutions that improve the human condition.
Mr. Panetta oversees several subsidiaries of Biocom, including a Purchasing Group that provides more than $100 million in products and services savings to members. He is co-founder of the Biocom Political Action Committee, the Biocom Institute for education and workforce development, and chairman of the California Biotechnology Foundation, a joint initiative to inform legislators and the media about the state’s life science sector. In 2014, Mr. Panetta was appointed by California Governor Jerry Brown to the Independent Citizens Oversight Committee, which serves as the governing and oversight board for the California Institute for Regenerative Medicine (CIRM) and is responsible for providing grant funding under the $3 billion California Stem Cell Initiative. He is past chairman of the Council of State Bioscience Associations (CSBA) and founding chairman of the State Medical Technology Alliance (SMTA)
Mr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College, and a Master of Public Health degree in industrial and environmental health from the University of Pittsburgh. He is a graduate of the Brookings Institution Program for Executives and the Harvard Program on Negotiation. Mr. Panetta brings a depth of experience to his role, having worked in policy in Washington, D.C. and in regulatory affairs in the life science industry before joining Biocom in 1999.
Mr. Panetta serves on the boards of directors of the San Diego Regional Economic Development Corporation, the San Diego Regional Chamber of Commerce, and CONNECT. He is a past chairman of the board of the San Diego Workforce Partnership. Mr. Panetta is a member of advisory boards of the Pharmacy School at UC San Diego, the Engineering school at San Diego State University, the College of Science and Mathematics at Cal State University San Marcos, and the National University School of Business and Management. He has received the following awards: the American Academy of Pharmaceutical Physicians Special Recognition Award; the CONNECT Distinguished Contribution Award for Life Science Innovation; and the Association of Pan Asian Communities Annual Leadership award, among others.
Bernard Munos, MBA
Senior Fellow – Faster Cures & Founder, InnoThink Center for Research in Biomedical Innovation
Bernard Munos is a Senior Fellow at FasterCures, a center of the Milken Institute, and the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Before that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. He is also a member of the National Academy of Medicine’s Drug Forum; a member of the Advisory Board of Science Translational Medicine; a non-executive Director of Glenmark Pharmaceuticals; a Board member or Advisor to a dozen other companies or publicly-financed research organizations; and a former member of the Advisory Council of the National Institutes of Health’s National Center for Translational Sciences (NCATS). His research has been profiled by Forbes magazine; and the popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma. He received his MBA from Stanford University, and holds other graduate degrees in animal science and agricultural economics from the Paris Institute of Technology for Life, Food and Environmental Sciences and the University of California, Davis. He blogs about biomedical innovation on the Forbes website.
Managing Director and Global Head of Life Sciences Practice , Parthenon-EY,
Kristin is a Managing Director of Parthenon-EY and Global Head of the Life Sciences practice. Based in the Boston office, she has 20 years of experience in the life sciences sector. Kristin is serving clients in the pharmaceutical, biotech, diagnostics and life science tools industries, with a focus on company and investor commercial strategy and M&A support for diagnostics, life science research and pharmaceutical companies. She is also the creator and leader of EY Precision Medicine™.
Prior to joining EY in 2013, Kristin was a partner and owner of Health Advances, where she managed the firm with four other partners and developed and led a global Diagnostics and Life Sciences practice focused on product and service strategy, corporate strategy, health economics and deal diligence. She is also a founder of DxInsights, a nonprofit organization designed to educate the nation’s health care communities on the impact of diagnostics in improving health care outcomes.
Kristin earned a BA in Biochemistry from Smith College and an MS in Epidemiology, Health Management, and Maternal and Child Health from the Harvard School of Public Health.
David A. Shaywitz, MD, Ph.D.
Chief Medical Officer, DNAnexus
Dr. Shaywitz is the Chief Medical Officer of DNAnexus, where he focuses on product-market fit, working closely with the DNAnexus team of scientists and engineers, and with external partners and collaborators. Most recently at Theravance Biopharma, he focused on strategy, new product planning, and business development, and led a product team. Previously, he was a management consultant at the Boston Consulting Group, working with Top 5 Biopharma clients on both R&D and commercial engagements. Before that, he was an early member of the Department of Experimental Medicine at Merck Research Labs. Dr. Shaywitz was also a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH). He has also served as a venture fellow at Fidelity Biosciences (now F-Prime Capital). He graduated summa cum laude from Harvard, received his MD from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his PhD from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton’s lab at the Harvard Stem Cell Institute. He currently serves as a visiting scholar (adjunct) in the Department of Biomedical Informatics at Harvard. He writes regularly for about medical innovation for Forbes, and contributes commentaries to a range of leading publications. He is co-author, with Lisa Suennen, of “Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology?,” and co-hosts, with Lisa Suennen, the bimonthly Tech Tonics podcasts, focused on “the people and passion at the intersection of technology and health.”
Bernard Parker, MBA.
Managing Director, Caligen Bio
Bernard Parker is managing director at Caligen Bio, where he advises emerging life science companies on business development and commercialization strategy. Possessing two decades of pharmaceutical and biotech leadership in the U.S. and internationally, Bernard has led novel corporate, business unit, and product growth initiatives while holding influential leadership roles at innovative companies including Ignyta, Novartis, Amgen, and Bain & Co. Bernard was previously at San Diego-based biotech Ignyta, Inc., where he was responsible for commercial development of a portfolio of pre-clinical and clinical-stage precision oncology drug candidates. Before that, Bernard spent 5+ years at Novartis AG in Europe, where he initially focused on growing a Munich-based oncology biosimilars portfolio from zero to $100 million in revenues and later served as head of a $1 billion specialty pharmaceuticals franchise based in Geneva, Switzerland.
Prior to Novartis, Bernard was a management consultant at Bain & Company, where he focused on corporate strategy, commercial due diligence, and operational improvement. Earlier, he held sales and marketing roles at Amgen Oncology and Parke-Davis/Warner Lambert (now Pfizer). Bernard earned an M.B.A. from Harvard Business School and a B.A. in Biological Sciences magna cum laude from Hampton University. He conducted biomedical research at the National Institutes of Health, who granted him a Medical Scientist Training Program fellowship to pursue an M.D./Ph.D. at Baylor College of Medicine.
Richard Kronick, Ph.D.
Professor, Department of Family Medicine & Public Health, UCSD
Richard Kronick, PhD, a Professor in the Department of Family Medicine and Public Health at UC San Diego recently returned from a sabbatical in Washington D.C. where he served as Director of the Agency for Healthcare Research and Quality (AHRQ). He previously served as Deputy Assistant Secretary for Health Policy at Health and Human Services in Washington D.C. from 2010 – 2013. His work at UC San Diego focuses on understanding the causes and consequences of lack of insurance, and on understanding whether and how markets can be made to work in health care, particularly for vulnerable populations. He has developed and helped state Medicaid programs implement risk-adjusted payment systems for payment to HMOs.
Hudson Freeze, Ph.D.
Director and Professor, Human Genetics Program, Sanford Children’s Health Research Center, Sanford Burnham Prebys Medical Discovery Institute
Hudson H. Freeze, PhD, is a Professor of Glycobiology and Director of the Human Genetics Program at Sanford-Burnham Medical Research Institute (SBMRI) in La Jolla. Dr. Freeze is a Past President of the Society for Glycobiology and is the first representative from that Society to serve on the FASEB Board of Directors.
Dr. Freeze has earned nearly 40 years of continuous NIH funding in Glycobiology, beginning with his postdoctoral work. In the last 18 years he focused on the identification and understanding of human genetic disorders, the Congenital Disorders of Glycosylation (CDG), which now number over 100. He collaborates closely with physicians, families and their support organizations and regularly consults on cases while still tracking the genetic basis of multiple patients with unknown glycosylation defects.
Prior to his 25 years at SBMRI, Dr. Freeze was a member of the UCSD School of Medicine faculty, and continues there as an Adjunct Professor. He isolated the first extreme thermophile, Thermus aquaticus (Taq), for which he won the 2013 Golden Goose Award.
Standish Fleming, MBA
Managing Member, Forward Ventures
A 30-year veteran of early-stage venture capital investing, Mr. Fleming has helped raise and manage six venture funds totaling more than $500 million and has served on the boards of 19 venture-backed companies. He has extensive experience in all aspects of venture management and finance, including fundraising,
investor relations, operations and portfolio development. He has made investments, managed portfolio companies, raised funds, pursued business development, taken companies public and successfully exited investments through public-market sales and buyouts.
In 1993, Mr. Fleming co-founded Forward Ventures. He has made investments in almost every segment of the health-care industry, including pharmaceuticals, biologics, diagnostics, devices, services and software. He has managed both platform and product companies/investments in the portfolio and led or participated in financings at all levels from pre-start-up to PIPES in public companies, in both debt and equity. He has helped start more than 15 companies and served as founding CEO of eight.Mr. Fleming serves as a director of CONNECT, San Diego’s support organization for the academic-to-earlystage community, and is a past president of the Biotechnology Venture Investors Group. Before establishing Forward Ventures, He served as the chairman, president and CEO of GeneSys Therapeutics (merged with Somatix and acquired by Cell GeneSys [NASDAQ:CEGE]). He began his venture career with Ventana Growth Funds in San Diego in 1986. He earned his B.A. from Amherst College and his M.B.A. from the UCLA Graduate School of Management.
Edward Abrahams, Ph.D.
President, Personalized Medicine Coalition
Edward Abrahams, Ph.D., is the president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously, Dr. Abrahams was the executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier, he had been assistant vice president for federal relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has taught history and public policy at Brown University and the University of Pennsylvania.
PhD Candidate, University of Mississippi School of Pharmacy, Graduate Research Assistant, St. Jude Children’s Hospital
Nicholas Keeling has been a graduate research assistant with St. Jude Children’s Research Hospital for the past several years while working towards his PhD from the School of Pharmacy at the University of Mississippi. In his role at St. Jude, Nick works with Dr. James Hoffman, the Chief Patient Safety Officer and leader on the PG4KDS preemptive pharmacogenetics protocol.
Nick’s research thus far has focused on the translational science of pharmacogenetics and the preemptive testing model. Prominent academic health centers throughout the U.S. have implemented preemptive pharmacogenetic testing protocols. His work has been presented to several NIH sponsored multi-center research consortiums that support these protocols, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Implementing GeNomics In pracTicE (IGNITE), as well as others with commercial interests. Nick looks forward to future work in developing health policy strategies for efficient implementation of genomic and other med tech innovations.
Prior to beginning his doctoral studies, Nick worked for several years in healthcare consulting focused on strategy and market access for new pharmaceuticals and medical devices. Nick holds a BA in Economics, BM in Classical Voice, and MS in Pharmaceutical Science from the University of Mississippi
Edward Tsai, MBA, MPH
Founder & CEO, Base Four
Edward Tsai is a precision medicine strategy executive focused on translating scientific advancements into revenue opportunities. Edward is the Founder and CEO of Base Four Inc., a precision medicine technology and consulting startup, specializing in strategy and data monetization.
Prior to launching Base Four, he led strategy for the precision medicine arm of Children’s Hospital Los Angeles and was a strategy consultant for PricewaterhouseCoopers (PwC) focused primarily in precision medicine. In these roles, he helped identify new markets, evaluate competitive environments, commercialize technologies, and develop business plans and financial models to capitalize on emerging trends in precision medicine; specifically, at the intersection of genetics, biotechnology, and digital technology.
Gregory Light, Ph.D.
Professor and Deputy Vice Chair of Education and Training in the UCSD Department of Psychiatry, UCSD
Dr. Gregory Light is a Professor and Deputy Vice Chair of Education and Training in the UCSD Department of Psychiatry. Dr. Light also serves as the Director of Mental Health Research and the Director of the Mental Illness, Research, Education and Clinical Center (MIRECC) at the VA San Diego Healthcare System. In these roles, he provide leadership, supervision, and administrative support across several clinical, education, and multidisciplinary research programs. Dr. Light has published over 120 peer-reviewed papers (h-index=49). This work has been prominently featured in policy reports from the Institute of Medicine for next-generation strategies for personalized treatments of psychotic disorders.
Kathryn A. Phillips, Ph.D.
Founding Director, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy Director, UCSF
Kathryn A. Phillips, PhD, a health services researcher and health economist and leader in the application of new technologies to improve healthcare, is the founding director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy at the University of California, San Francisco (UCSF). She is also a professor of health economics and health services research in the Department of Clinical Pharmacy at UCSF, with additional appointments in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center
Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is personalized (or precision) medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).
Kathryn has published ~150 peer-reviewed articles in major journals, including JAMA, the New England Journal of Medicine, and Health Affairs and has had continuous funding from the US. National Institutes of Health as a principal investigator for 25 years. She currently serves on the editorial boards of the journal Health Affairs (rated as the top policy journal), Value in Health (a leading outcomes research journal), and all of the leading journals on personalized medicine. Kathryn has served on national and international scientific advisory committees and workshops including work Board of Directors for GenomeCanada, National Academy of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to various international and industry organizations, including more than 35 biotechnology companies and venture capital firms. She was recently awarded a Rockefeller Foundation global and worked with thethe Patient-Centered Outcomes Research Institute (PCORI) – the largest funder of comparative effectiveness research in the world – developing a research agenda on personalized/precision medicine.
M. Arthur Moseley, Ph.D.
Associate Research Professor Director, Duke Proteomics Core Facility, Duke University
Arthur Moseley is the Director of Proteomics and Metabolomics for the School of Medicine at Duke University. He holds leadership positions in the Center for Genomic and Computational Biology and the Center for Applied Genomics and Precision Medicine. At Duke, he is responsible for the development and application of proteomic and metabolomics technologies for open (unbiased) qualitative and quantitative UPLC/MS/MS analyses using high resolution, accurate mass tandem mass spectrometers coupled with ultra-performance nanoscale capillary liquid chromatographs, and for targeted quantitation using UPLC/MS/MS with multiple reaction monitoring (MRM).
The Proteomics and Metabolomics Shared Resource has the variety of capabilities for support of a diverse range of basic research projects, and the capacity for support of clinical trials. The clinical support has included biomarker discovery in studies in the areas of neurology, oncology, immunology, and infectious disease. Prior to his position at Duke University, he managed mass spectrometry laboratories at GSK for sixteen years, and for the last six years of these years he lead a transnational laboratory (US/UK) dedicated to proteomic biomarker discovery. Dr. Moseley received his MS in Physical Chemistry from North Carolina State University, and his PhD in Analytical Chemistry from the University of North Carolina at Chapel Hill. His dissertation, under the direction of Professor Jim Jorgenson, addressed the coupling of nanoscale separation with tandem mass spectrometry for the analysis of peptides and proteins.
Marian Rewers, MD, Ph.D.
Professor of Pediatrics and Medicine Executive Director, Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine
Dr. Rewers is a pediatric endocrinologist who has dedicated his research to finding the cause and prevention of type 1 diabetes (T1D). His clinical team serves 7000 children and adults with T1D. His research is based on NIH-funded cohort studies: Diabetes Autoimmunity Study in the Young (DAISY) and The Environmental Determinants of Diabetes in the Young (TEDDY) following over 11,000 high-risk infants to learn how genes and the environment interact in causation of T1D and celiac disease. The Autoimmunity Screening for Kids (ASK) program is now translating findings from DAISY and TEDDY to public health screening for and prevention of T1D and celiac disease. In the Coronary Artery Calcification in Type 1 (CACTI) study, his team has discovered a number of novel genetic, metabolic, and inflammatory factors of potential importance for prevention of diabetic complications. Dr. Rewers has helped to train the next generation of investigators in clinical and translational research, including a number of pediatric endocrinologists. Together, they have published more than 400 original articles and reviews in the area of diabetes. Together, they have published more than 450 research articles and reviews in the area of diabetes.
Rohit Loomba, M.D.
Gastroenterologist and Hepatologist Vice Chief, Gastroenterology Director, Hepatology Professor of Medicine
Rohit Loomba, MD, is a board-certified gastroenterologist. His expertise includes treating and managing many types of chronic liver disease, such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis, chronic hepatitis, cirrhosis, and hemochromatosis. As a transplant hepatologist, Dr. Loomba works with transplant surgeons in the pre and postoperative care of liver transplant patients. He also directs the NAFLD Research Center at UC San Diego, and leads a multidisciplinary group of investigators to study NAFLD.
Dr. Loomba believes in providing compassionate and state-of-the-art care to his patients. He also believes in the importance of strong physician-patient relationships for improving medical decision making and delivering high quality care in a friendly environment.
As a professor in the Division of Gastroenterology, Dr. Loomba instructs students, residents and fellows in the Department of Medicine at UC San Diego School of Medicine. His research focuses on all aspects of NAFLD, including prevalence in aging, epidemiology, genetic and environmental predisposition and progression.
An advocate of evidenced-based medicine, Dr. Loomba has led numerous clinical trials to help find innovative treatments for people suffering from liver illness. He also serves as the director of the Nonalcoholic Steatohepatitis (NASH) Clinical Research Network at UC San Diego. Sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, the NASH Clinical Research Network aims to facilitate and perform clinical, epidemiological and therapeutic research in nonalcoholic steatohepatitis.
Dr. Loomba is widely published, having co-authored more than 150 articles. His work has appeared in Gastroenterology, Hepatology, and Clinical Gastroenterology and Hepatology, among others. He also reviews for many journals, including Annals of Internal Medicine, Gastroenterology, The American Journal of Gastroenterology, and several others.
Dr. Loomba completed a fellowship in gastroenterology at UC San Diego School of Medicine and a fellowship in hepatology at the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD) in Betheseda, M.d. He completed a residency in internal medicine at St. Luke’s Hospital in St. Louis. While in residency, he was selected for his clinical and leadership abilities to serve as chief resident. Dr. Loomba earned his medical degree from the Armed Forces Medical College in Pune, India. He obtained a Master of Health Science in clinical research from Duke University School of Medicine in Durham, N.C. Dr. Loomba is board-certified in internal medicine and gastroenterology.
He is a member of numerous professional societies, including the American Association for the Study of Liver Diseases, the American Gastroenterology Association, and the American Society for Gastrointestinal Endoscopy, among others.
Wayne W. Grody, M.D., Ph.D
Professor in the Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, and the Institute for Society and Genetics, at the UCLA School of Medicine
Wayne W. Grody, M.D., Ph.D. is a Professor in the Departments of Pathology & Laboratory Medicine, Pediatrics, and Human Genetics, and the Institute for Society and Genetics, at the UCLA School of Medicine. He is the director of the Molecular Diagnostic Laboratories and the Clinical Genomics Center within the UCLA Medical Center, one of the first such facilities in the country to offer DNA-based tests for diagnosis of a wide variety of genetic, infectious, and neoplastic diseases, as well as bone marrow engraftment, patient specimen identification and paternity testing by DNA fingerprinting, and clinical genomic DNA sequencing for undiagnosed disorders. He is also an attending physician in the Department of Pediatrics, specializing in the care of patients with or at risk for genetic disorders (with a special interest in familial Mediterranean fever, among others), and director of the UCLA Intercampus Medical Genetics Training Program. In addition, he is heavily involved in basic molecular genetics research involving regulation of gene expression of arginase and related enzymes in hereditary arginase deficiency and various cancers, population molecular genetic screening, and construction of artificial human mutation samples. He has been one of the primary developers of quality assurance and ethical guidelines for DNA-based genetic testing for a large number of governmental and professional agencies including the FDA, AMA, CAP, ACMG, ASHG, NCCLS/CLSI, CDC, AMP, VA, ACGME, and the NIH-DOE Human Genome Project (ELSI program). He served as a member of the NIH-DOE Task Force on Genetic Testing, and was the working group chair for development of national guidelines for cystic fibrosis and factor V-Leiden mutation screening. He served for five years as founding chair of the Advisory Committee on Genomic Medicine for the entire VA healthcare system, and is Past President of the American College of Medical Genetics. Recent awards include the Lifetime Achievement Award from the College of American Pathologists, the Ward Burdick Award for Distinguished Service from the American Society for Clinical Pathology, the Bowes Award Lectureship at Harvard Medical School, the Roscher Endowed Lectureship of the International College of Surgeons, the Leadership Award from the Association for Molecular Pathology, and the Golden Apple Teaching Award from the UCLA Intercampus Medical Genetics Training Program. As a sidelight, Dr. Grody has been active in the film and television industries for many years, first as film critic for MD Magazine, a national leisure journal for physicians, then as technical advisor and sometime writer for a number of feature films, TV movies, and television series including Life Goes On, Chicago Hope, CSI, Medium, Law and Order, Heroes, and both Nutty Professor movies. He did his undergraduate work at Johns Hopkins University, received his M.D. and Ph.D. at Baylor College of Medicine, and completed residency and fellowship training at UCLA. He is double-board-certified by the American Board of Pathology (Anatomic and Clinical Pathology, Molecular Genetic Pathology) and the American Board of Medical Genetics (Clinical Genetics, Molecular Genetics, Biochemical Genetics).
Wainright Fishburn, JD
Partner – Cooley, LLP
M. Wainwright Fishburn, Jr. is a founding partner of Cooley’s San Diego office and a prominent venture capital lawyer. Wain’s practice emphasizes general representation of life science, technology and other operating companies that range from startup through IPO. His practice focuses on corporate governance
matters as well as mergers, acquisitions, strategic alliances, and intellectual property licensing and management. He also assists his client companies in financing matters, often involving the placement of debt and equity securities.
As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues, including a keynote at the 2014 and 2015 International CES Digital Health Summit, USC’s Body Computing Conference, Impact Forum and the Wireless-Life Sciences Alliance’s
Convergence Summit. Wain has also served as Co-Chair of the BIO Digital Health Forum at the BIO International Convention from 2014-2016. As a community leader, Wain is immediate past Chairman of the Sanford-Burnham Institute for Medical Research, one of the nation’s leading independent biomedical research institutes. He recently joined The Executive Committee of the Board of the UCSD Moores Cancer Center where he is afforded a clinical perspective for the application of breakthroughs in genomic medicine and serves as on the organizing committee for the Center for Personalized Cancer Therapy. He serves as Vice Chair of the Critical Path Institute, an independent, non-profit organization dedicated to bringing scientists from the FDA. He is a founding director of both the Corporate Directors Forum and BIOCOM, the largest regional life science association in the world, representing more than 550 member companies and is a member of its Executive Committee
Patrick Lilley, MBA
Chief Data Scientist, Liquid Biosciences
Liquid Biosciences’ mission is to make healthcare more effective and less expensive, with fewer harmful effects. The company’s bio-inspired signal processing technology is used to predict treatment response, disease progression, and adverse events, as well as for diagnostics and multi-omics biomarker discovery. The company’s customers include pharmaceutical companies and healthcare service organizations. Patrick has spent the last 25 years driving growth and innovation in biotech, software, high-performance computing, and mobile wireless. He holds patents in artificial intelligence, disease prognosis, and specialized algorithms. He has guest lectured at CalTech, MIT, Stanford, Berkeley, USC, Brandman University, and UC Irvine. He holds a BA in Economics and an MBA specializing in quantitative finance, both from UC Irvine.
James C. Robinson, Ph.D., MPH
Leonard D. Schaeffer Professor of Health Economics, Director, Berkeley Center for Health Technology, Division Head, Health Policy and Management
School of Public Health, University of California
James Robinson is Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. He serves on a variety of professional boards and advisory boards, including the Integrated Healthcare Association and National Institute for Health Care Management, and as contributing editor for Health Affairs journal. Professor Robinson gives numerous keynote speeches and board presentations for medical technology firms, health insurance plans, hospitals, medical groups, universities, and public agencies.
At Berkeley, Professor Robinson’s research focuses on the biotechnology, medical device, insurance, and health care delivery sectors. He has published three books and over 130 papers in peer-reviewed journals such as the New England Journal of Medicine, JAMA, and Health Affairs. His most recent book, “Purchasing Medical Innovation: The Right Technology for the Right Patient at the Right Price” analyzes the roles of the FDA, health insurers, hospitals, and consumers in the assessment, purchasing, and use of high-cost implantable devices. Professor Robinson’s econometric research currently centers on the impact of reference pricing on consumer choices and employer spending for surgical procedures, laboratory tests, diagnostic imaging, and pharmaceuticals.
V.P. Payer Innovation, Alva 10
Lena has spent her career studying reimbursement and the managed care industry from the perspective of diagnostics. She believes that reimbursement, as one of the most misunderstood and dynamic aspects of healthcare, is ripe for innovation.
Leveraging her background in biology and mathematics, Lena is working to match the price of new diagnostics to payer value through improvements in the reimbursement process. Lena most recently led the reimbursement strategy of QIAGEN’s global molecular diagnostics portfolio and has broad experience in diagnostics commercialization, sales, contracting, and reimbursement. Earlier, she held multiple leadership roles at AmniSure International until its successful strategic sale. She has personally performed every step in the reimbursement spectrum of a diagnostic, and takes both a product-specific and portfolio-wide view of the healthcare products she brings to payers. She is passionate about driving reimbursement toward value-based care, and bringing clarity and change to a field that healthcare reform has put into flux.
Senior Solutions Architect, Intel Corporation
Andy Bartley is a Senior Solutions Architect in the Health & Life Sciences Organization at Intel Corporation. His focus areas are client technology and predictive analytics for healthcare providers. In his role Andy serves as a trusted adviser to stakeholders across the care continuum to aid in the development of leading-edge technology solutions that improve the provider and patient experience and enable healthcare delivery systems to deliver new models of care.
Andy has a diverse background in healthcare including senior operations roles at Stryker, VP of Business Development for One Medical Group and as Co-founder of Algorithms.io and NurseGrid. He is a regular speaker on the topic of innovation and is active in developing entrepreneurial communities in emerging markets .
Mitsuyuki “Mickey” Matsumoto, Ph.D.
Executive Director, Candidate Discovery Science Labs, Astellas Pharma
Dr. Matsumoto currently heads the Unit 2, Candidate Discovery Science Labs. at Astellas Pharma Inc. located in Tsukuba, Japan and is responsible for discovery of new therapeutics for neuropsychiatric and immune disorders. Dr. Matsumoto received his B.S. (1988), M.S. (1990) and Ph.D. (1997) from the University of Tokyo. After joining Astellas predecessor Yamanouchi Pharmaceutical Co, Ltd. in 1990, he led the G-protein coupled receptor (GPCR) group in discovering novel GPCRs and their ligands. Dr. Matsumoto served as a Visiting Scholar (2001 – 2003) at the National Institute of Mental Health (NIMH), USA, under Drs. Daniel Weinberger and Joel Kleinman, where he was involved in dedicated studies of schizophrenia genetics and pathophysiology. After Astellas Pharma Inc. emerged from a merger of Yamanouchi and Fujisawa, Dr. Matsumoto established a CNS research group at Astellas Research Institute of America LLC in Skokie, Illinois (2008 – 2014). In 2012, Dr. Matsumoto was the first member of the Japanese pharmaceutical industry nominated as a member of American College of Neuropsychopharmacology (ACNP). He has served as an Adjunct Professor at Northwestern University, USA (2009-2017).
Gerard Marek, MD, Ph.D.
Global Medical Lead, Astellas Pharma
Gerard Marek earned his MD and PhD (Psychopharmacology) at the University of Chicago in 1989 and 1988. After completing residency training in Psychiatry at the Yale University in the School of Medicine, he spent another 3 years as a post-doctoral fellow studying single cell electrophysiological recordings in rat brain slices. He then obtained independent RO1 funding after securing a junior faculty position in the Yale Department of Psychiatry in 1997 combining slice electrophysiology with independent neurochemical and behavioral studies. In January 2002, Gerard joined the Pfizer early clinical development group in Groton working on antidepressants and antipsychotic drugs. He moved to Eli Lilly in Oct 2003 and spent the majority of 5 years at Lilly leading a Discovery group in Psychiatric Disorders targeting novel antidepressants, antipsychotics, novel treatments for substance abuse and sleep disorders. Gerard then spent 6 years in Neuroscience Clinical Development at AbbVie mostly directed toward developing medications for the symptomatic treatment of Alzheimer’s disease and disease progression of multiple sclerosis with respect to remyelination and neurite sprouting. He moved to Astellas a little over 3 years ago where he has been leading programs studying cognitive impairment associated with schizophrenia and chronic pain syndromes.
William Potter, MD, Ph.D.
Senior Advisor to the NIMH
Dr. Potter earned his B.A., M.S., M.D., and Ph.D. at Indiana University, after which he held positions of increasing responsibility and seniority over the next 25 years at the National Institutes of Health (NIH) focused on translational neuroscience. Currently he serves as a Senior Advisor to the NIMH Director. Earlier at the NIH, Dr. Potter was widely published and appointed to many societies, committees, and boards; a role which enabled him to develop a wide reputation as an expert in psychopharmacological sciences and champion the development of novel treatments for central nervous system (CNS) disorders. Dr. Potter left the NIH in 1996 to accept a position as Executive Director and Research Fellow at Lilly Research Labs, specializing in the neuroscience therapeutic area and in 2004 joined Merck Research Labs as Vice President of Clinical Neuroscience, then the newly created position of Translational Neuroscience in 2006. His experience at Lilly and MRL in identifying, expanding, and developing methods of evaluating CNS effects of compounds in human brain cover state-of-the-art approaches across multiple modalities. These include brain imaging and cerebrospinal fluid proteomics (plus metabolomics) as well as development of more sensitive clinical, psychophysiological, and performance measures allowing a range of novel targets to be tested in a manner that actually addresses the underlying hypotheses. He has become a widely recognized champion for the position that more disciplined hypothesis testing of targets in humans is the best near term approach to moving CNS drug development forward. He has authored more than 200 publications in the field of preclinical and clinical pharmacology, mostly focused on drugs used in affective illnesses and methods for evaluating drug effects in humans. He has received many honors during his career, including the 1975–1977 Falk Fellow, American Psychiatric Association; 1986 Meritorious Service Medal, U.S. Public Health Service; and, in 1990, St. Elizabeth’s Residency Program Alumnus of the Year Award.
Pamila Brar, MD
Medical Director, Human Longevity Health Nucleus
Dr. Pamila Brar joined the HLI team in July 2015 as Medical Director of the Health Nucleus. Pam graduated from LSU Medical School in 1995 at age 23, and moved to San Diego to complete her Internal Medicine training. She was awarded the title of Ellen Browning Scripps Chief Medical Resident at Scripps Clinic La Jolla in 1999. After serving several years as a Scripps Clinic concierge physician, she started her own concierge medical practice in La Jolla in 2009 where she thrived.
Active in the American Academy of Private Physicians, a national organization dedicated to private medicine and healthcare innovation, Pam became an AAPP conference speaker, board member, and then served as the organization’s president from April 2015 to 2017. In recent years, Pam appeared regularly as a health consultant on San Diego news stations and honed her skills in communication. Despite her success in private practice, Pam’s love for science led her to join HLI in May 2015 as Medical Director of the Health Nucleus. This endeavor has allowed her to leverage her private medicine, leadership and business modeling experience to collaboratively grow a disruptive health intelligence delivery model. Utilizing whole genome sequencing, advanced imaging and omics, the Health Nucleus is a pioneer in the field of early detection and personalized medicine. The opportunity to collaborate with scientific visionaries including Craig Venter and Karen Nelson has been among the highlights of Pam’s career.
Ralph Riley, MBA
Co Dx Market Access Leader for the Co Diagnostic Commercial Strategy Group in Janssen Global Services
Ralph Riley, MBA is the Co Dx Market Access Leader for the Co Diagnostic Commercial Strategy Group in Janssen Global Services. He provides leadership in support of development, commercialization and policy related to companion and standalone “complementary” diagnostics in the areas of oncology, neuroscience, infectious disease, cardiovascular/metabolic disease and immunology. He has more than twenty-years of experience (twelve- years with J&J) in pharmaceutical, medical devices and diagnostics industries including tenure in sales, marketing, analytics and market access.
Ralph has co-authored several papers articulating the value of diagnostics and personalized medicine, lead research in epidemiology and modeling the use of bio-markers for chronic disease and has spoken at many personalized medicine and access focused conferences regarding opportunities for evidence generation and access strategy related to testing.
Market Development, Roche Diagnostics Information Systems
Kimberley Ferguson is a Market Development and Account Executive with Roche Diagnostics Information Solutions. In this role, Kimberley is identifying and maturing bioinformatics driven opportunities in focused healthcare settings, including; academic medical centers, oncology clinical decision support and tumor boards. Kimberley is a tenured sales professional as well as a scientist, and holds dual Bachelor of Science degrees in Microbiology and Biochemistry from San Diego State University.
Kimberley has spent the past three years focusing on both the coalescence of large clinical data sets in disparate healthcare settings, and the utilization of “omics,” to facilitate data driven discovery from bench to bed-side. She spent a year and a half as the Executive Vice President of Sales and Marketing at Signet Accel, a technology start-up in Columbus, Ohio – that focused on an interoperability platform in the healthcare IT arena. Kimberley also spent a year and half working for Illumina and during this time she was focused on the tumor board setting and clinical decision support tools that enhanced discussions focused on the “genomics” aspect of cancer treatment. Kimberley has more than twenty years of sales experience in healthcare including ten and half years at Roche Diagnostics.
Kimberley’s varied background in sales, healthcare, informatics, marketing and hospital diagnostics have provided the perfect foundation for developing the market and selling informatics solutions in oncology settings in Roche’s newest business endeavor – to digitize healthcare.
Donald Jones, JD, MBA
Chief Digital Officer at Scripps Translational Science Institute, Cardiff Ocean Group Chairman
Donald Jones is a globally recognized leader in Digital Medicine – the Internet of Medical Things and technology enabled health services. He is a sought out as a speaker, advisor and board member. He works across a spectrum of healthcare, pharmaceutical, medical device, wearable, apparel, material science, Telco and early stage companies. He serves on the Boards of Directors of venture capital backed companies and with strategic investors including GE, Telus, Qualcomm, Reed Elsevier and Adidas. His Fortune 1000 Advisory Board roles include Flex, TEVA, JSR, Sanofi, McKinsey and MAS. Jones serves as Chief Digital Officer of the Scripps Translational Science Institute (STSI), collaborating with the renowned Eric Topol, MD, on the convergence of genomics and digital health. He co-founded with Eric Scripps Digital Medicine, the world’s first digital health clinical trial center and the non-profit West Health Institute, raising over $130 million. STSI now holds the largest NIH grant in history, part of the ‘All of Us’ Precision Medicine Initiative.
For 11 years, Don led Qualcomm’s Wireless Health Global Strategy and Business Development and founded its healthcare division. In 2005 he founded and is now Chairman Emeritus of the Wireless Life Sciences Alliance. In 2016 WLSA merged with the HIMSS Personal Health Care Alliance (PHCA), forming a global trade, standards, scientific and professional organization. Earlier in his career, Donald was COO of MedTrans, which grew from $4.5M into the largest emergency services provider in the US, operating with more than 22,000 paramedics and 5,500 ambulances. He was Founder and Chairman of EMME, the largest consumer subscription based healthcare provider in Mexico, employing over 500 physicians. While advising the Board of American Medical Response, he helped build the largest medical group in the US, under the EmCare brand. Ultimately, MedTrans acquired AMR and EmCare, both now part of Envision Healthcare, a $10B public healthcare company. EvoNexus recognized Donald Jones as 2014 Digital Health Innovator of the Year. Don conceived the $10 million Qualcomm Tricorder XPRIZE, a global competition with 134 entrants, for a consumer device which successfully makes medical diagnoses. The prize was awarded in Hollywood in April 2017.
Stephen F. Kingsmore, MD, DSc
President and CEO of the Rady Children’s Institute for Genomic Medicine
After a comprehensive search process, Stephen F. Kingsmore, MD, DSc was appointed as the inaugural President and CEO of the Rady Children’s Institute for Genomic Medicine in September 2015. Previously he was the Dee Lyons/Missouri Endowed Chair in Genomic Medicine at the University of Missouri-Kansas City School of Medicine and Director of the Center for Pediatric Genomic Medicine at Children’s Mercy Hospital, Kansas City. He has been the President and CEO of the National Center for Genome Resources, Santa Fe, New Mexico, Chief Operating Officer of Molecular Staging Inc., Vice President of Research at CuraGen Corporation, founder of GatorGen, and Assistant Professor at the University of Florida’s School of Medicine. Dr. Kingsmore received MB ChB BAO BSc and DSc degrees from the Queen’s University of Belfast. He trained in clinical immunology in Northern Ireland and did residency in internal medicine and fellowship in rheumatology at Duke University Medical Center. He is a fellow of the Royal College of Pathologists. He was a MedScape Physician of the year in 2012, and received the 2013 Scripps Genomic Medicine award and 2013 ILCHUN prize of the Korean Society for Biochemistry and Molecular Biology. TIME magazine ranked his rapid genome diagnosis one of the top 10 medical breakthroughs of 2012. In March of 2015, Dr. Kingsmore surpassed his previous record in genetic sequencing by reducing the process to 26 hours which was recognized in April 2016 by Guinness World Record as the fastest genetic sequencing in the world.
Hartmuth Kolb, Ph.D.
Head of Neuroscience Biomarkers, Johnson & Johnson
Hartmuth Kolb, Ph.D., is the Head of Neuroscience Biomarkers at Janssen Research & Development. He and his team work on multi-biomarker disease signatures (protein, genomics, electrophysiology, imaging) for improving patient selection, patient sub-typing and treatment monitoring related to Alzheimer’s Disease and depression related disorders.
Hartmuth is chemist by training, with 25 years of experience in the pharmaceutical industry as well as academics. He received his PhD in Organic Chemistry in 1991 at Imperial College of Science, Technology and Medicine, London, UK. Following postdoctoral work with K. Barry Sharpless (2001 Chemistry Nobel Laureate), he joined Ciba-Geigy in 1993. In 1997, Dr. Kolb became the Head of Chemistry at Coelacanth Corporation. In this role, he and Dr. Sharpless developed the Click Chemistry approach to drug discovery. In 2002, he joined The Scripps Research Institute as an Associate Professor, focusing on in situ Click Chemistry. From 2004 to 2013, he was the head of the Siemens Biomarker Research group, where he and his team developed novel oncology and neurodegenerative disease PET tracers, key highlights being the PHF-Tau PET tracers [18F]-T808 and [18F]-T807 (aka AV-1451, Flortaucipir). Dr. Kolb joined Janssen in January 2014. He has authored and co-authored over 90 peer-reviewed publications, which have received over 24,000 citations, and is inventor on 48 issued patents.
Benedict Paten, Ph.D.
Assistant Professor, Dept. of Biomedical Engineering, UC Santa Cruz
Benedict Paten is an assistant professor in the Department of Biomedical Engineering at the University of California, Santa Cruz. At UCSC he directs the Computational Genomics Lab (https://cgl.genomics.ucsc.edu/), a group of faculty, research scientists, engineers and students creating cutting edge methods for understanding the genomic basis of health and disease. He holds degrees in neuroscience and computer science, and a PhD in computational biology jointly from the University of Cambridge and the European Molecular Biology Laboratory.
Vijay Chandru, Ph.D.
Executive Chairman & Co-Founder, Strand Life Sciences
Vijay Chandru (PhD, MIT ‘82) is an academic turned entrepreneur. A professor of computational mathematics first at Purdue University and then Indian Institute of Science, Vijay is a fellow of the national academies of science and engineering in India. A Technology Pioneer of the World Economic Forum since 2006, Vijay has been on the global agenda council for the future of healthcare at WEF for 2014-2016. He is a founder and former Honorary President of ABLE (the apex body for the biotechnology industry in India) from 2009-2012 and continues as a special invitee to the executive council.
As an entrepreneur, Vijay leads the new generation healthcare company Strand Life Sciences. Since 2007, Strand has been a global leader in bioinformatics products licensed to over 2000 research labs and hospitals worldwide. With a team of over 200 high calibre scientists, Strand is leading the charge in precision medicine in India with over 300 referring hospitals and clinics. Strand has the only CAP and ISO 15189 accredited lab for clinical genomics using NGS technologies in South Asia.
Mark Punyanitya, MS
President, & CEO, PhenoMX
Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials. He is Founder, President, & CEO of the Image Reading Center, Inc., an Imaging Core Laboratory & Contract Research Organization developing Imaging Biomarkers for global multi-center Clinical Trials, and Co-Founder, President, & CEO of PhenoMx, Inc., commercializing a Personalized Digital Physical Examination for Precision Medicine, Personalized Wellness, and Human Longevity.
With over 15 years of experience in the implementation & standardization of medical imaging, Mark has published over 44 papers and his advances in body composition have been applied to a wide range of therapeutic areas. As a Biomedical Engineer, Mr. Punyanitya facilitates the translation of science, technology, & medicine for the development & commercialization of quantitative imaging biomarkers.
Andrea Ferris, MBA.
President & Chairman of the Board, LUNGevity Foundation
Andrea became passionate about lung cancer advocacy following her mother’s death from the disease in 2008. After receiving a diagnosis of stage IV lung cancer in 2006, Andrea’s mother underwent numerous treatments and clinical trials at several major academic institutions, to no avail. Together with her father, Andrea was her mother’s primary caregiver during this time. Determined to drive more money into lung cancer research, Andrea left the successful software company that she helped launch to found Protect Your Lungs, an organization focused 100% on funding early detection research. In 2010, Andrea merged Protect Your Lungs with LUNGevity, a Chicago based organization that also funds research to improve treatment options and offers support programs for survivors, to form the nation’s largest lung cancer-focused nonprofit.
Andrea’s strong business background combined with her connection to the worlds of research and advocacy have enabled her to build the preeminent patient advocacy organization in the lung cancer space. LUNGevity funds translational research into both early detection and more effective treatments of lung cancer as well as a highly coveted Career Development Awards program. LUNGevity also fills unmet needs for people diagnosed with lung cancer by providing education and support programs. Recognizing the need to raise funds for research and build awareness and understanding about lung cancer, LUNGevity has built the largest grassroots network of events and advocates across the country.
Mary Stevens, MBA.
Director of Network Contracts, Compliance & Audit at Blue Cross and Blue Shield of Minnesota
Mary Stevens is the Director of Network Contracts, Compliance & Audit at Blue Cross and Blue Shield of Minnesota and oversees all aspects of contract drafting, regulatory filings, contract compliance, and division audit activities for open access as well as managed care networks. In this position she is responsible for the design and control of the documents inside of regulatory, accreditation, corporate, and other standards and rules. Her prior experience includes financial underwriting, self-insured TPA benefit plan design and implementation, and fully insured contracting oversight. Mary’s expertise encompasses the areas of network management, regulatory, accreditation, and audit compliance, and alignment of benefit plan design to network design. Mary also taught credit courses for insurance continuing education for 8 years and holds a BA from the University of St. Catherine and an MBA from the University of St. Thomas.
Amylynne Santiago Volker
President and Founder, Nicholas Volker One in a Billion Foundation.
Amylynne was born in Chicago Illinois, and raised in rural South central and Madison, WI where she currently resides. She serves as the Founder and President of the Nicholas Volker One In A Billion Foundation a 501(c)(3) nonprofit organization with a mission to Inspire the world to improve the quality of life
for those with undiagnosed and rare disease by advancing the practice of personalized and genomic medicine. Amylynne is the mother of five children including her son Nic who is widely celebrated as the first person in the world saved by DNA sequencing and described as one of the faces of the Human Genome Project by Francis Collins.
As Nic battled a life threatening, mysterious illness over the course of several years, it was in part Amylynne’s unrelenting pursuit of answers and tireless advocacy for her son that led to the historic sequencing of his DNA & ultimately the bone marrow transplant that saved his life. A Pulitzer Prize Winning Series “One in a Billion: A boy’s life; a medical mystery” and a book published by Simon and Schuster “One in a Billion the Story of Nic Volker and the Dawn of
Genomic Medicine” were both written largely based on Amylynne’s Caringbridge Journal which chronicled Nic’s fight to live and their medical and diagnostic odyssey. Amylynne now fights for patients and families with undiagnosed, rare and or life threatening illnesses and is well known in the community for her healthcare Advocacy and Activism.
Amylynne started healthcare initiatives in WI that have become law, lobbies regularly on behalf of patients with special needs for improved health care policy at the state and federal level and as a Rare Disease Legislative Advocate in Washington D.C. Amylynne has met with the Speaker of the House Paul Ryan on multiple occasions and other members of Congress in a quest for additional funding for the NIH and garner support for the recently passed 21st Century Cures Legislation. Amylynne has also privately met with the Director of the National Institutes of Health to advocate for targeted research and soon will be launching a Natural History Study and Registry for pediatric patients with XIAP and NLRC4 @www.oneinabillionic.com.
Matthew McManus, MD, PhD.
President and CEO, Asuragen., Inc.
Dr. McManus joined Asuragen in August 2014 bringing more than 20 years of clinical diagnostic leadership experience. Matt was most recently CEO and President of PrimeraDx, Inc., a molecular diagnostics company acquired by Qiagen. He has held leadership positions in a number of other companies, including Head of Cleveland Clinic Laboratories, COO of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic, and a variety of positions at Novartis, McKinsey & Co., and Procter & Gamble. Dr. McManus received his MD and PhD from the University of Pennsylvania, MBA from Boston College and BA from the College of the Holy Cross.
Ross Higgins, MBA.
Director of Laboratory Operations, OneOme
Ross Higgins joined OneOme in early 2016 and holds responsibility for organizing and directing laboratory operations for the company. Most recently, Ross served in a dual business development and product management role for Douglas Scientific, where he was responsible for driving both product development and market expansion efforts. Ross also brings extensive experience in the clinical laboratory field, owing to several years managing the molecular genetics department at a large, CAP-accredited reference laboratory. Ross has a B.S. in Clinical Laboratory Sciences and an M.B.A. from Virginia Commonwealth University. He also maintains ASCP certification as a Medical Laboratory Scientist.
Chief Operating Officer – Congenica Ltd.
Nick was previously Director of the NE Thames Regional Genetics Service at Great Ormond Street Hospital for Children, with responsibility for the strategic and operational management of a genetics service that provides DNA diagnostic testing to a population of approximately 4.5M people. Nick is an honorary Reader at the UCL Institute of Child Health, and has over 25 years of research experience in human molecular genetics. He was awarded a personal chair in Medical Genetics at Cardiff University in 2005 and is a founding CEO of London Genetics Ltd and Programme Director at Oxagen Ltd.
Medical Director – Congenica Ltd.
Phil is a consultant physician and Professor of Medical and Molecular Genetics at the UCL Institute of Child Health (ICH), an NIHR Senior Investigator, an Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital (GOSH) and the lead on Personalised Medicine for UCL. He is an internationally recognized expert in the genetics and pathogenesis of ciliopathies and pioneering use of next generation sequencing in mapping disease genes in this area.
WALTER (Buzz) STEWART, PhD, MPH
Chief Research Officer – Sutter Health
Buzz Stewart, Chief Research Officer, joined Sutter Health in July 2012. He oversees research organized around Digital Health and Advanced Analytics, Precision Care & Medicine, Clinical Trials, and Rapid Health System Learning. Buzz has transformed the research model at Sutter to be translation focused and strategic in supporting Sutter as a Learning Health Care System. His personal interests span the unique role of health system research in transforming care through predictive analytics, population health management, and digital health.
Prior to Sutter, Buzz founded the Geisinger Center for Health Research (2003-2012), a research and development unit that participated in Geisinger’s decade long strategy to transform the delivery of health care. Previously, he was a faculty member at the Johns Hopkins Bloomberg School of Public Health (1983-1995), was Vice President of Research and Development at AdvancePCS (1998-2002) and founded several successful start-ups.
He has published more than 400 peer-reviewed articles (h-index>105) and book chapters after receiving his PhD in Epidemiology from Johns Hopkins University, his MPH from UCLA, and his BS in Psychobiology from University of California, Riverside.
Vice President of Payer Relations & Reimbursement, Foundation Medicine Inc.
Jerry Conway, Vice President of Payer Relations & Reimbursement, joined Foundation Medicine Inc. in May 2012 with over 22 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces working first in physician sales and marketing, then later with national and regional payers on contracting, education and utilization management initiatives involving laboratory services. His experience includes payer contracting and reimbursement in a wide range of business environments including Fortune 500 and start-up companies. In 2011, Jerry joined Metamark Genetics Inc., a national provider of cancer prognostic tests and services, as Vice President of Reimbursement & Payer Contracting. At Metamark, Jerry was responsible for payer strategy development for several assays in the pre-launch phase. In 1997, Jerry joined Genzyme Genetics, a national provider of genetic health services, to develop business relationships and contracts with regional and national payers based in the Northeastern United States. In 2001, he was promoted to the role of Director of National Accounts with Genzyme Genetics and was responsible for business development and contracts with national and cross-regional payers. In 2004, Jerry was promoted to Vice President of Managed Care where he oversaw a staff of 11 regional and national account directors who were focused on payer account management, contracting, pull through, education and care management programming. With a particular focus on reimbursement for routine and novel genetic tests and services in the reproductive and oncology markets at Genzyme Genetics, Jerry has a demonstrated track record of increased revenue and profitability. Under his leadership in payer contracting and reimbursement over 14 years, Jerry helped to favorably position the company for a recent $975 million acquisition by Laboratory Corporation of America® Holdings on December 1, 2010.
Valerie A. Schneider, Ph.D.
Staff Scientist, National Center for Biotechnology Information
Dr. Schneider received her Ph.D. from Harvard University in 2001 and did her post-doctoral training at the University of Pennsylvania School of Medicine (2001-2007). Since 2008, she has been a Staff Scientist at the National Center for Biotechnology Information (NCBI). NCBI is a member of the GRC (Genome Reference Consortium), the group responsible for updating the human, mouse, zebrafish and chicken reference genome assemblies. Dr. Schneider leads the team of curators and developers at NCBI responsible for the analysis and data management of the GRC assemblies, as well as the development of tools for assembly QA and curation. Her team is also responsible for the development of tools and infrastructure used for genome visualization and analysis, including the NCBI genome browser suite, and the NCBI Genome Remapping Service. As the head of the Sequence View program at NCBI, she oversees the development of a variety of web-based and stand-alone resources that help users take advantage of the wealth of genomic data that is now available in the public sphere.
Katlin McKelvie Backfield, JD.
Founding Partner, Backfield PLLC
Katlin McKelvie Backfield advises companies on issues related to the regulation of pharmaceuticals. With over 15 years of experience in the area of pharmaceutical regulatory law, including more than 10 years at the Food and Drug Administration, she uses her extensive expertise to help companies navigate the pre- and post-approval stages of drug development. Katlin served as Associate Chief Counsel for D ugs with the Office of Chief Counsel at FDA for nine
years. She was a regulatory counsel in the Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research at FDA from 2006 to 2008.
Prior to joining FDA, Katlin was an associate at Hogan Lovells, LLP, and a law clerk for the Honorable Douglas P. Woodlock of the U.S. District Court for the District of Massachusetts. She graduated cum laude from Georgetown University Law Center and received her undergraduate degree from Davidson College.
Katlin is a member of the Food and Drug Law Institute’s Academic Programs Committee. She has developed and conducted training workshops for employees across FDA and for the Food and Drug Law Institute’s Introduction to Drug Law course.
Anna D. Barker, Ph.D.
Co-Director, Complex Adaptive Systems (CAS), Director, National Biomarker Development Alliance (NBDA)
As Co-Director of CAS, Dr. Barker designs and implements new research models specifically directed toward addressing major problems in biomedical research and biomedicine. CAS at ASU serves as an organizing construct to understand and solve multi-dimensional problems in the biomedical and health sciences. These multi-sector networks are the foundation for the development of new research models that leverage convergent knowledge and novel funding approaches to understand and improve the diagnosis and treatment of complex diseases.
Prior to joining ASU, Dr. Barker served several years as the Deputy Director and Deputy Director for Strategic Scientific Initiatives for the NCI, National Institutes of Health (NIH). At the NCI Dr. Barker developed and led or co-led a number of trans-disciplinary programs including: Nanotechnology Alliance for Cancer, The Cancer Genome Atlas (TCGA); and the Clinical Proteomics Technologies Initiative. Dr. Barker also led a multi-year effort to plan and implement a new trans-disciplinary research construct to enable the convergence of the physical sciences (physics, mathematics, physical chemistry and engineering) with cancer biology. Under her leadership, the NCI developed major initiatives in bio specimen science and bioinformatics. She was founding co-chair of the NCI-FDA Interagency Task Force (IOTF) and founding co-chair of the Cancer Steering Committee of the FNIH Biomarkers Consortium (FNIH-BC). She also oversaw the NCI’s international cancer research programs, including pilot programs in Latin America and China. Prior to joining the NCI, she co-founded and served as CEO of a public biotechnology company preceded by several years at Battelle Memorial Institute where she served as vice president of the Institute’s biomedical research sector.
Her research interests include complex adaptive systems and applications in biomedical research; disease, biomarker(s) discovery and development; advanced clinical trial models; and experimental therapeutics and free-radical biochemistry in cancer etiology and treatment. Dr. Barker received her B.S. from Morehead State University; and her M.A. and Ph.D. at the Ohio State University, where she trained in immunology and microbiology.
Elizabeth Baca, MD.
Senior Health Advisor in the Governor’s Office of Planning and Research
Dr. Elizabeth Baca is passionate about innovations to foster total health and well-being. She currently serves as the Senior Health Advisor in the Governor’s Office of Planning and Research (OPR). She is engaged in innovation in the public sector to foster health through multiple projects including healthy planning, big data, and public-private partnerships. For healthy planning she works across sectors to foster collaboration, elevate the connection between health and the built environment, and leads the effort to incorporate health considerations into the planning process to build healthy, resilient communities. A significant part of her work is aligning win-wins for projects that offer co-benefits, particularly with respect to climate mitigation and adaptation efforts. For big data, she is working on projects to link data sets to the planning process. Additionally, she serves as a lead for the Governor’s Initiative to Advance Precision Medicine. Through her role in OPR, she is an advisor for the USGBC Building Health Initiative and FS6, a new Food System Accelerator.
Previously, she served on the General Pediatric Faculty at Stanford Medical School and directed the Community Pediatric and Child Advocacy Rotation. In addition to teaching medical students and residents about the social, economic, and environmental factors that affect health, Dr. Baca was the lead faculty mentor on several projects to increase access to healthy foods, reduce environmental triggers of asthma, increase physical activity opportunities, and improve the built environment.
Dr. Baca studied health p
licy at Universidad Simon Bolivar in Venezuela. She completed her Masters in Public Administration at Harvard Kennedy School of Government and her Doctorate of Medicine at Harvard Medical School. Dr. Baca completed her pediatric residency in the Pediatric Leadership for the Underserved (PLUS) program at University of California, San Francisco.
Jennifer Pearce, MPA
Founder, Plain Language Health
A passionate advocate for patient engagement through understanding, Jennifer brings 18 years of experience collaborating with researchers, providers and patients to advance health literacy.
In 2012 she founded Plain Language Health, a consultancy that specializes in co-producing care and research content patients can easily understand and act on. Previously, Jennifer led Sutter Health’s award-winning health literacy initiatives, as well as patient experience research within the 24-hospital system. Prior to joining Sutter, she led national patient engagement efforts for five NIH-funded genetic studies of autoimmune disease at the University of California San Francisco.
Jennifer’s work has been recognized by the Institute for Healthcare Advancement and the Center for Plain Language in Washington, D.C., earning ClearMark Awards of Distinction in 2012 and 2013. She currently serves on the Center’s board of directors.
Jennifer earned her MPA in Healthcare Administration from California State University East Bay and her BA from the University of California, San Diego.
Riley Bove, MD
UCSF Multiple Sclerosis Center, and an Assistant Professor in the UCSF Department of Neurology
Riley Bove, MD (co-Investigator) is a board-certified neurologist practicing at the UCSF Multiple Sclerosis Center, and an Assistant Professor in the UCSF Department of Neurology. She obtained her undergraduate degree from Harvard College, her MD from Harvard Medical School, and completed her neurology training and multiple sclerosis (MS) research fellowship in the joint Massachusetts General Hospital and Brigham and Women’s Hospitals Partners program.
Her research interest in MS is to identify new strategies and targets to promote neurological recovery, including through emerging technologies and hormonal modulation. Since joining UCSF, she has been promoting the advancement of precision medicine in MS care by expanding the accessibility of the MS BioScreen (neurology.ucsf.edu/research/ms-bioscreen). New developments include an open access patient-facing Open MS BioScreen, as well as a clinically actionable tool that sits directly on the electronic medical record at Sutter (MS-SHARE).
Her work has been funded by the National Institutes of Health, the National MS Society, the California Initiative to Advance Precision Medicine, and the Conrad Hilton Foundation, among others.
Zakiuddin Ahmed, MBBS
Project Director RAH@H, King Saud University
Dr. Zakiuddin Ahmed is a visionary strategist, healthcare entrepreneur & a physician leader who specializes in developing socially beneficial. sustainable, scalable and innovative solutions in Healthcare through information technology
Areas of Interest/Expertise: eHealth / mHealth, Digital Healthcare Marketing, Healthcare Quality, Healthcare Leadership, eLearning, Ethics, Strategic Planning & Patient Centric Health Advocacy
Maurice Treacy, PhD MBA
Strategic Relationships, Co-Founder Genomics Medicine Ireland
Maurice has over 20 years’ executive leadership experience in the biotech, pharma and life-science sectors, with extensive experience in innovative scientific research and drug development.He is former CEO and co-founder of HiberGen, a startup genomics-based drug development company and was a Director of Life Sciences at Science Foundation Ireland (SFI) and CEO of the National Institute for Bioprocess Research & Training (NIBRT). Most recently, he was Venture Partner with ARCH Venture Partners and with the Growcorp Group, an Irish VC firm. Maurice holds a PhD in Pharmacology from UCD and a MBA from Northeastern University. He is an Adjunct Professor at the UCD Smurfit Business School. He is a co-inventor on over 80 USA patents applications.
Robert Loberg, Ph.D.
Director Medical Sciences, Head of Clinical Biomarkers and Diagnostics, Amgen
Robert Loberg, PhD, Director Medical Sciences, is the Head of Clinical Biomarkers and Diagnostics at Amgen and is responsible for discovery, development and execution of biomarker and diagnostic strategies to support the Amgen portfolio across all therapeutic areas. Dr. Loberg leads a team of biomarker scientists and computational biologists in pursuit of biomarker and diagnostic driven drug development efforts. Dr. Loberg joined Amgen in 2009 in the Oncology Biomarker group within Medical Sciences. He served as the Biomarker Lead for multiple oncology programs and was responsible for biomarker discovery and development activities of clinical candidates from pre-First in Human studies through clinical development. In addition, he led an active lab-based research group charged with technology evaluation and biomarker discovery/implementation to support the biomarker needs of a growing pipeline. In 2013, Robert assumed the role of Director Medical Sciences / Therapeutic Area Lead, Clinical Biomarkers – Oncology and was responsible for management of discovery, development and execution of biomarker strategies across the Oncology portfolio.
Dr. Loberg received his B.A. degree in biology from Baylor University and Ph.D. from The University of Michigan. He completed his post-doctoral training in a prostate cancer biology laboratory. Following his post-doctoral fellowship he joined the faculty at The University of Michigan as an Assistant Professor in Internal Medicine and Urology where he continued his research in prostate cancer. Dr. Loberg has authored more than 50 peer reviewed scientific publications and is involved in a number of scientific consortia advancing translational medicine in drug development and medical research.
Daniel H. Mathalon, Ph.D., M.D.
Professor of Psychiatry, UCSF
Daniel Mathalon, Ph.D., M.D. is a Professor in the Departments of Psychiatry at the University of California, San Francisco. He directs the Early Psychosis Program at UCSF and the Brain Imaging and EEG Laboratory located at the San Francisco VA Medical Center, where he also serves as Chief of General Psychiatric Outpatient Services. Dr. Mathalon received a B.A. in Psychology from U.C. Berkeley, a Ph.D. in Psychology from Indiana University, and an M.D. from Stanford University. He completed his psychiatric residency training and a research fellowship in Psychophysiology at Stanford University. Following this training, he joined the Psychiatry faculty at Yale University, and after 8 years, he moved to his current position at UCSF. Dr. Mathalon uses EEG and MRI based measures to study brain dysfunction in neuropsychiatric disorders, particularly schizophrenia. A major focus of his work has been to identify neurophysiological biomarkers of risk for schizophrenia among individuals exhibiting putatively prodromal symptoms. Current efforts are focused on examining abnormalities in neural plasticity as a basis for gray matter loss and neurocognitive impairments in schizophrenia.
Christopher A. Longhurst, MD, MS
Chief Information Officer, UC San Diego Health
Clinical Professor of Biomedical Informatics and Pediatrics, UC San Diego School of Medicine
As Chief Information Officer, Dr. Longhurst is responsible for all operations and strategic planning for information and communications technology across the multiple hospitals, clinics, and professional schools which encompass UC San Diego Health. Dr. Longhurst is also a Clinical Professor of Biomedical Informatics and Pediatrics at UC San Diego School of Medicine, and continues to see patients. He previously served as Chief Medical Information Officer for Stanford Children’s Health and Clinical Professor at the Stanford University School of Medicine, where he helped lead the organization through the implementation of a comprehensive electronic medical record (EMR) for over a decade. This work culminated in HIMSS stage 7 awards for both Lucile Packard Children’s Hospital and 167 network practices in Stanford Children’s Health.
Dr. Longhurst has published dozens of scientific articles in peer-reviewed journals on how technology and data can improve patient care and outcomes and was elected as a fellow in the prestigious American College of Medical Informatics, among other distinctions. He is a board-certified pediatrician and clinical informaticist, and founded Stanford’s fellowship in clinical informatics, first in the nation to receive accreditation. Described as a pragmatic academician, Dr. Longhurst, serves as an advisor to several companies and speaks internationally on a wide gamut of healthcare IT topics
Nigam H. Shah, MBBS, PhD
Associate Professor of Medicine (Biomedical Informatics Research) and Bilogical Data Science, Stanford University
Bryce Olson is the Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.
Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four who are also cancer survivors.
Global Marketing Director, Health and Life Science, Intel Corporation
Bryce Olson is the Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.
Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four who are also cancer survivors.
Frederick J. Meyers, MD, MACP
Associate Dean for Precision Medicine & Professor of Internal Medicine / hematology-oncology at UC Davis School of Medicine
Dr. Frederick Meyers is the Associate Dean for Precision Medicine and professor of internal medicine / hematology-oncology at UC Davis School of Medicine. He has served UC Davis as chief of hematology-oncology, chair of the Department of Internal Medicine and vice dean of the School of Medicine.
Dr. Meyers has a long-standing interest in cancer biology, with a focus on advanced and metastatic malignancies. His earliest publications in the molecular oncology of urologic cancers emphasized clinical trials with laboratory correlative studies. He recognized the inherent ethical conflict between early-phase cancer clinical trials and the need to deliver palliative and end-of-life care. Many of his early grants and publications highlighted this apparent paradox that he resolved by developing a model of simultaneous or concurrent care. The systems-based improvement of cancer-care delivery integrated cancer therapy and palliative care at the same time, rather than sequentially, and changed the paradigm of the care of patients with both advanced malignancy and nonmalignant illnesses, successfully introducing palliative care earlier in the trajectory of illness. This forms the basis for his ongoing commitment to quality of care improvement, and he has long been an advocate for integrating QI into health sciences education.
Dr. Meyers is strongly committed to the career development of junior scholars, MD and PhD, pre-and postdoctoral. He directs the Research Education and Career Development core of the UC Davis NIH-funded Clinical Translational Science Center (CTSC). His commitment is reflected in his service as principal investigator of several training grants including the CTSC Mentored Clinical Research Training Program, a California stem cell research training grant and a grant from HHMI Integrating Medicine into Basic Sciences. He is PI of the UC Davis NIH Common Fund Broadening Experiences in Scientific Training (BEST) award. His current focus is leading and integrating precision medicine across all of the colleges and schools at UC Davis and the communities it serves.
President & CEO, Biotheranostics, Inc.
Don Hardison has more than 30 years of executive leadership experience in both emerging and Fortune 500 companies, including roles as CEO and COO, as well as a board member. Most recently, Don served as president, CEO, and director of Good Start Genetics, Inc. He also served in a similar capacity at EXACT Sciences Corp., where he was actively involved in taking the company public and was primarily responsible for a novel multi-million dollar strategic partnership with Laboratory Corporation of America (LabCorp). He has extensive experience in diagnostic laboratory management, sales, marketing, strategy, operations and broad reimbursement expertise. Don also has held multiple senior leadership positions at companies such as LabCorp, Quest Diagnostics, and SmithKline Beecham Corp., where he built a strong track record in strategy development, team building, and market planning and execution.
Iya Khalil, PhD
Chief Commercial Officer and Co-Founder, GNS Healthcare
Dr. Khalil is a technology entrepreneur and physicist with a vision of transforming medicine into a discipline that is quantitative, predictive, and patient-centric via big data analytic approaches. She co-founded two big data companies, Via Science and GNS Healthcare, and is the co-inventor of the proprietary computational engine that underpins both entities. She trained in theoretical physics at Cornell University, and has more than 11 years of experience in “big data” analytics for healthcare, medicine, and the life sciences.
She has led several key foundational collaborations with providers, pharmaceutical companies, foundations, and government agencies. Dr. Khalil’s expertise spans applications in drug discovery, drug development all the way to treatment algorithms that can be applied at the point of care. She is a frequent speaker at industry events and conferences, has appeared in several industry journals, published several articles in the field, and was recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine. More recently, she was named to the PharmaVOICE 100 list of the most inspiring people in the life sciences industry. She was recognized for her ability to build bridges across the life science and healthcare industries, bringing people together to harness the power of predictive modeling to change the lives of patients.
Patricia Carrigan, Ph.D.
Global Head of Translational Assay Technology, Bayer AG
Patricia Carrigan, Ph.D. has over 20 years of experience in the life science industry focusing the majority of her time on Biomarker discovery/translational research, and the development of Companion Diagnostics. Currently, she is the Global Head of Translational Assay Technology for Bayer AG focusing her team efforts on bringing cutting edge technologies/ biomarker strategies to Oncology, Women’s health, and Cardiovascular Phase I/II clinical trials. In addition her team also oversees the technical and regulatory development strategies for Bayer’s RX-CDx co-development programs. Prior to Bayer, Patricia built a high performing team as a Senior Manager of Assay Development at Roche-Ventana where her team was responsible for developing robust prototype Immunohistochemical and In Situ Hybridization assays. Some of the key programs that she managed which are now at the forefront of Immuno-oncology and Precision Medicine include PDL1, ROS, ALK, and BRAFV600E IHC Companion Diagnostics.
In her earlier years Patricia worked at the International Genomics Consortium and the Molecular Profiling Institute. At IGC, she was the Director of Assay Development and manager of the Biospecimen Core Repository which was the main supplier of tumor material for the Cancer Genome Atlas Pilot Program. While at the Molecular Profiling Institute which is now Caris, she helped develop and validate the Target Now panel, which is now referred to Caris’s Moleculer Intelligence Panel. She holds a Ph.D. in Biochemistry and Molecular Biology from the Mayo Clinic College of Medicine, Rochester Minnesota.
Fred H. Gage, Ph.D.
Adler Professor, Laboratory of Genetics, The Salk Institute
Adjunct Professor, UCSD
Fred H. Gage, Ph.D., a Professor in the Laboratory of Genetics, joined The Salk Institute in 1995. He received his Ph.D. in 1976 from The Johns Hopkins University. Dr. Gage’s work concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. In addition, he models human neurological and psychiatric disease in vitro using human stem cells. Finally his lab studies the genomic mosaicism that exists in the brain as a result of mobile elements that are active during neurogenesis.
Prior to joining Salk, Dr. Gage was a Professor of Neuroscience at the University of California, San Diego. He is a Fellow of the American Association for the Advancement of Science, a Member of the National Academy of Sciences and the Institute of Medicine, and American Philosophical Society, a foreign member of the European Molecular Biology Organization and a Member of the American Academy of Arts and Sciences.
Dr. Gage has served as President of the Society for Neuroscience in 2002, and past President for the International Society for Stem Cell Research 2012.
Vice President, Policy & Research, Pharmaceutical Research and Manufacturers of America
Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.
Mr. Burkholder has over 20 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.
Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.
Thomas A Bock, MD, MBA
Chief Executive Officer of HeritX
Dr. Thomas Bock is the Chief Executive Officer of HeritX, a global R&D organization focused on stopping inherited gene mutations from turning into cancer, starting with BRCA cancers. HeritX’s pipeline of targeted pre-cancer interventions (PCIs) includes enhancers of genomic stability as well as pre-cancer vaccines.
Dr. Bock believes that precision medicine can make its greatest impact through pre-disease intervention, the only way to achieve a world without disease. Dr. Bock’s broad experience in cancer and ultra-orphan diseases spans academic medical research, the US National Institutes of Health and the biopharmaceutical industry.
Following his research on stem cell and genetic therapies at the National Human Genome Research Institute as well as his oncology medical practice and research at international cancer centers, Dr. Bock served in European and global leadership roles at Amgen, Novartis Oncology, and Celgene. Prior to founding HeritX, he served as Senior Vice President of Global Medical Affairs and member of the executive management team of Alexion, rated #2 in innovation across all industries (Forbes).
Dr. Bock has built entrepreneurial teams and organizations driving the global medical programs of more than 15 therapies and product launches, including life-saving breakthroughs such as the first targeted cancer therapy, the first immune-modulatory cancer therapy and the first complement inhibitor for autoimmunity.
Dr. Bock’s focus on alliances across academia, industry, and the patient community has propelled medical progress for patients with multiple diseases, and is a pillar of HeritX’s accelerated R&D platform for rapidly turning research ideas into to available therapies. Dr. Bock has received numerous scientific and professional awards.
Robert Sebra, Ph.D.
Associate Professor, Department of Genetics and Genomic Sciences, Icahn Institute of Genetics and Multiscale Biology, Mount Sinai
Robert Sebra, Ph.D. leads Technology Development at the Icahn Institute of Genetics and Multiscale Biology and Sema4 Genomics and Associate Professor in the Department of Genetics and Genomic Sciences. He pioneers technology adoption, and research and development to create high-throughput diagnostics and innovative molecular biology techniques to generate high-resolution data applying bulk and single cell sequencing technologies for clinically driven applications. Dr. Sebra has published more than 50 papers in top tier journals, including Science, Cell, Nature, NEJM, and Cancer Discovery, and his work has led to multiple issued patents.
Since establishing a team at Icahn School of Medicine at Mount Sinai, Dr. Sebra has applied WGS and targeted genomics approach toward a better understanding of genomic variation for higher resolution human disease diagnostics in cancer and inherited disease, alongside infectious disease surveillance using both long- and short-read sequencing techniques. Prior to his work at Sinai, Dr. Sebra was involved in research and development contributing to single molecule real-time long read sequencing technology and applications at Pacific Biosciences after receiving his Ph.D. in Chemical and Biological Engineering at University of Colorado, Boulder.
David Spetzler, Ph.D., MBA
Chief Scientific Officer, Caris Life Sciences
Dr. David Spetzler joined Caris Life Sciences in August of 2009, and has held several management positions with increasing responsibilities during his tenure. He currently serves as President and Chief Scientific Officer and provides executive leadership for the company’s service lines, Caris Molecular Intelligence® and ADAPT Biotargeting System™.
Under his leadership, the R&D team is focused on the development of clinical assays to aid in the creation of precision medicine strategies for individual cancer patients, as well as noninvasive technologies to identify and predict early stage cancer. Much of work is focused on the development of the ADAPT Biotargeting System™, a groundbreaking and proprietary method of profiling macro-molecular complexes in their native form in a highly multiplexed format. The innovative technology is the result of the convergence of Caris’ deep expertise in Next-Generation Sequencing, exosome biology, bioinformatics and broad-based molecular profiling.
Prior to his position at Caris, Dr. Spetzler was a member of the research faculty at Arizona State University where he developed multiplexed nanotechnologies for single molecule detection of nucleic acid and protein targets. He also developed novel methods of using DNA to create biological computers to solve NP-complete optimization problems, and built a novel optical detection system capable of measuring single molecule protein conformational changes with microsecond time resolution. At Arizona State University Dr. Spetzler earned an MS from the School of Mathematical and Statistical Science in Computational Bioscience, a Ph.D. in Molecular Cellular Biology and an MBA. Dr. Spetzler is an adjunct faculty member of the molecular cellular biology program at Arizona State University, a scientific and commercial reviewer for SBIR/STTR grants for NSF, co-authored more than twenty patents, and has published numerous research articles.
Eric Glassy, M.D.,FCAP,
Director of Pathology, Providence Little Company of Mary Medical Center.
Dr. Glassy is a community pathologist in Southern California and director of pathology at Providence Little Company of Mary Medical Center, San Pedro. He is a member of Affiliated Pathologists Medical Group, a 40 person independent pathology group covering 15 hospitals and laboratories in California, Portland and Phoenix. Dr. Glassy has won a number of pathology awards, including the Distinguished Service Award and Excellence in Education Award from the College of American Pathologists (CAP). He has chaired hospital and CAP national committees. He served as chairman of the Hematology and Clinical Microscopy Resource, Publications, Digital Pathology and Curriculum Committees. He is a past Board Member of the CAP Foundation and a graduate of the Engaged Leadership Academy. He is president of the Digital Pathology Association. He edited, wrote and illustrated several pathology color atlases and developed software programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma. He is a trustee of the American Board of Pathology as well as a board of governor of the College of American Pathologists.
Bruce Quinn, M.D.,Ph.D.,
Principal, Bruce Quinn Associates LLC
Bruce Quinn, M.D., Ph.D., partners with the leadership of innovative companies to craft successful business strategies in digital health and life sciences. With a nationwide client base, Dr. Quinn has worked successfully with both large and small companies in overcoming hurdles to commercialization through negotiation, understanding insightful ways to use the existing healthcare system to advantage. Dr. Quinn has helped stakeholders change federal policies in multiple domains and is an expert on the Medicare system.
Dr. Quinn travels nationwide to speak on health reform issues and publishes actively, including a widely read blog, “Discoveries in Health Policy,” which updates readers on federal policy changes in precision medicine as well as other health topics. In 2016, he published “Digital Health: Impact on Genomics,” a white paper describing digital genomics as a unique industry.
Before establishing Bruce Quinn Associates LLC, Dr. Quinn was a physician executive in the health and life sciences division of Accenture, working with the pharma, biotech and genomics industries. He also served as the regional Medicare medical director for the California Part B program, where he had authority for final coverage decisions on approximately 15 percent of the U.S. Medicare program and he spearheaded innovative approaches to coverage of new technologies. For eight years, he worked full time for Washington-based policy and lobbying groups. Dr. Quinn holds an MD-PhD from Stanford University and an MBA from the Kellogg School of Management.
Karen Nelson, Ph.D.,
President, J. Craig Venter Institute (JCVI)
Dr. Karen E. Nelson is the President of the J. Craig Venter Institute (JCVI) and head of the Microbiome group at Human Longevity Inc., in La Jolla California. Prior to being appointed President, she held a number of other positions at the JCVI, including Director of JCVI’s Rockville Campus, and Director of Human Microbiology and Metagenomics in the Department of Human Genomic Medicine at the JCVI. Originally from Jamaica, Dr. Nelson received her undergraduate degree from the University of the West Indies, and her Ph.D. from Cornell University. She has authored or co-authored over 170 peer reviewed publications, edited three books, and is currently Editor-in-Chief of the journal Microbial Ecology. She also serves on the Editorial Boards of BMC Genomics, GigaScience, and the Central European Journal of Biology. She is also a member of the National Academy of Sciences Board of Life Sciences, a Fellow of the American Academy of Microbiology, an Honorary Professor at the University of the West Indies and a Helmholtz International Fellow. Dr. Nelson has extensive experience in microbial ecology, microbial genomics, microbial physiology and metagenomics. Dr. Nelson has led several genomic and metagenomic efforts, and led the first human metagenomics study that was published in 2006. Additional ongoing studies in her group include metagenomic approaches to study the ecology of the gastrointestinal tract of humans and animals, studies on the relationship between the microbiome and various human and animal disease conditions, reference genome sequencing and analysis primarily for the human body, and other -omics studies.
Jeanette McCarthy, MPH, PhD
Founder, Precision Medicine Advisors
Jeanette McCarthy, MPH, PhD is a UC Berkeley trained genetic epidemiologist and spent the early part of her career in industry at Millennium Pharmaceuticals before transitioning to academia. She currently holds adjunct faculty positions at UCSF and Duke University. Her previous research had focused on the genetic underpinnings of complex diseases, both infectious and chronic. More recently, she has become a leading educator in the field of genomic and precision medicine. Jeanette helped launch the first consumer-facing magazine in this field, Genome, and served as Editor-in-Chief from 2014-2016. She developed the first MOOC on precision medicine, offered through Coursera, and teaches at UCSF and UC Berkeley Extension as well. Jeanette is coauthor of the book, Precision Medicine: A Guide to Genomics in Clinical Practice (from McGraw Hill Education).
Li Liu, MD
Assistant Professor of Biomedical Informatics and Director of the Bioinformatics Core Facility, Arizona State University
Dr. Liu is an assistant professor of Biomedical Informatics and the director of the Bioinformatics Core Facility at Arizona State University. She holds an M.D. degree in Medicine and an M.S. degree in Information System. As a trained clinician and a bioinformatics researcher, she fully appreciates the critical roles genomic medicine and bioinformatics play in advancing precision medicine. By integrating genomic, phylogenetic, population genetic, statistical and machine-learning techniques, Dr. Liu and her research team investigate clinical and molecular signatures of human diseases, and develop novel computational methods to discover biomarkers for early diagnosis and accurate prediction of therapeutic responses for individual patients. Before joining ASU, Dr. Liu helped build and directed the bioinformatics core facility at University of Florida.
Elizabeth Mansfield, Ph.D.
Head of Regulatory Strategy , GRAIL
Elizabeth Mansfield is the Head of Regulatory Strategy at GRAIL. Prior to GRAIL, Liz was Deputy Office Director for Personalized Medicine and Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices (OIVD) in the Center for Devices at the FDA, where she developed a program to address companion and novel diagnostic devices. She also previously served as a Senior Policy Analyst in OIVD, managing policy and scientific issues, and served in other positions at the FDA including Scientific Reviewer and Genetics Expert. Previously at Affymetrix, Liz was the Director of Regulatory Affairs (2004-2006). She holds a PhD from Johns Hopkins University and completed further postdoctoral training at the National Cancer Institute (NCI) and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).
Adrijana Kekic, PharmD, BCACP, CTLC.
Program Director Outpatient Pharmacy Education, Mayo Clinic
Adrijana Kekic is a Program Director of Education, Outpatient Pharmacy at Mayo Clinic in Phoenix, Arizona. She is active in clinical care, research and lecturing and has been involved in development of pharmacogenomics services and education. She is a licensed pharmacist in Arizona.
Dr. Kekic earned the Doctor of Pharmacy degree from Midwestern University College of Pharmacy in Glendale, Arizona. She is board certified ambulatory care pharmacist through Board Pharmacy Specialties (BPS) and a member of BPS Ambulatory Care Committee. She holds a certification in Pharmacogenomics from University of Florida College of Pharmacy and is pursuing a Genomic Medicine certification from Stanford University.
Adrijana has served as an adjunct faculty at Midwestern University College of Pharmacy and an instructor, preceptor and residency preceptor at Mayo School of Medical Science. She is involved with several pharmacogenomics research projects and studies in palliative care, transplant care, anesthesia and cardiology. She sits on Pharmacogenomics Task Force at Mayo Clinic.
With two decades of clinical experience and expertise in medication therapy management , Adrijana continues to advance pharmacy practice and pharmacy leadership. She is a founder of a networking platform dedicated to high impact professional women in healthcare. She collaborated with Arizona State University (ASU), Harvard Medical School, Thunderbird School of International Business and University of Arizona.
Jerry SH Lee, Ph.D.
Deputy Director, Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, National Institutes of Health
Dr. Lee serves as a Health Sciences Director within the National Cancer Institute’s Office of the Director’s Center for Strategic Scientific Initiatives where he provides leadership and oversight in planning, developing, and implementing rapid strategic technology initiatives that keep the Institute ahead of the scientific curve of potential new exciting areas and discoveries.
Since its inception in 2003, the Center has supported more than 2,000 trans-disciplinary projects through programs such as the Innovation Molecular Analysis Technologies (IMAT), NCI Alliance for Nanotechnology in Cancer, The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Physical Sciences-Oncology Centers (PS-OC), Provocative Questions (PQ), and Cancer Target Discovery and Development (CTD2) network. These exploratory initiatives focus on the integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation of publicly available, broadly accessible, multi-dimensional data, knowledge, and tools to empower the entire cancer research continuum for patient benefit. In 2016, Dr. Lee was assigned to Office of the Vice President to serve as the Deputy Director for Cancer Research and Technology for the White House Cancer Moonshot Task Force. A few key efforts he helped coordinate include the Applied Proteogenomics OrganizationaL Learning and Outcomes Network (APOLLO), international collaborations to share molecular characterization datasets, the Blood Profiling Atlas in Cancer pilot, as well as co-chairing an interagency group focused on cancer data and technology policy issues.
Dr. Lee earned his bachelor`s degree in biomedical engineering and Ph.D. in chemical and biomolecular engineering from Johns Hopkins University, where he continues research as an adjunct associate professor. He is a member of the Innovation Policy Forum of the National Academies Board on Science, Technology, and Economic Policy, the Foundation for the NIH’s Biomarkers’ Consortium Cancer Steering Committee, the Health and Environmental Sciences Institute’s Board of Trustees, and the editorial board of Convergence Science Physical Oncology journal.
Razelle Kurzrock, MD
Senior Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy, Director, Clinical Trials Office, Team Leaders, Experimental Therapeutics, UCSD Moores Cancer Center, Chief, Division of Hematology and Oncology , UC San Diego School of Medicine
Dr. Razelle Kurzrock is known for developing the largest Phase 1 clinical trials department in the nation/world while at the University of Texas M.D. Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT for Profile-related Evidence Determining Individualized Cancer Therapy. This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that is more likely to work for their individual tumors.
At Moores Cancer Center, Dr. Kurzrock’s charge is broad, including not just growing and innovating the center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. This center focuses on precision medicine trials, using the most innovative genomically-targeted drugs and/or agents that arm the immune system. As a physician-scientist, Dr. Kurzrock brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also Chief of the Division of Hematology and Oncology in the UC San Diego School of Medicine. Dr. Kurzrock received her MD degree from the University of Toronto and has over 600 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of Phase I program building.
Dr. Kurzrock also has a strong history of building outstanding education/training programs. At University of Texas MD Anderson Cancer Center, she founded and directed the MS/PhD program (degree granting) in Human Biology and Patient-Based Research, as well as the Fellowship in Investigational Cancer Therapeutics. At UCSD Moores Cancer, she founded and directs the Fellowship in Personalized Cancer Therapy.
Dr. Kurzrock has four children and lives with her husband, Dr. Philip Cohen, a dermatologist, in San Diego, CA.
Mara Aspinall, MBA,
President & CEO – Health Catalysts
Aspinall is a healthcare industry leader and pioneer with a commitment to active civic involvement. Aspinall is the President and CEO of Health Catalysts, an investment and advisory firm dedicated to the growth of new healthcare companies. Aspinall is also Executive Chairman of GenePeeks, a computational genomics company leading a paradigm shift in genetic testing and personalized medicine. GenePeeks’ proprietary technology can identify the risk of passing on more than 1100 monogenic diseases to progeny through data mining the maternal and paternal genomes with pre-conception testing.
Aspinall is a member of the Board of Directors of Allscripts (NASDAQ:MDRX), Abcam plc (AIM:ABC), 3Scan, Blue Cross Blue Shield Arizona and Castle Biosciences.
Aspinall is the former President and CEO of Ventana Medical Systems, a division of the Roche Group, worldwide leader in development and commercialization of tissue-based cancer diagnostics. At Ventana, with her world class team, she led the company to new market success, more than two dozen major instrument and assay launches and global leadership in companion diagnostics.
Previously, Aspinall spent 12 years with Genzyme as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics was sold to LabCorp for $1 billion in 2010. Aspinall was also Founder and CEO of On-Q-ity, a start-up diagnostic company dedicated to circulating tumor cells.
With a passion for education about the importance of diagnostics, Aspinall co-founded the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the first school ever dedicated entirely to Diagnostics as an independent discipline. The School awarded their first Master degrees in the summer of 2015 and will graduate Master’s students this year.
Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine. She served as an active member of the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in both the Obama and Bush administrations. Aspinall was also a Trustee of the Dana Farber Cancer Institute for 11 years, where she chaired the Trustee Science Committee.
Within Arizona, Aspinall is the Chair of the Arizona Biosciences Board, a CEO group focused on increasing opportunities in the state for technology companies. She is also a Board member of the Southern Arizona Leadership Council and Sun Corridor.
Aspinall is a frequent international speaker and author on healthcare related issues. She was named Arizona Biosciences Leader of the Year in 2016 by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine.
Mara started her business career at the strategic consulting firm Bain & Company. She holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.
Nick van Terheyden, MD
Founder & CEO, Incremental Health
Dr. Nick brings a distinctive blend of medical practitioner and business strategist, both national and international, to the realm of healthcare technology. A graduate of the Royal Free Hospital School of Medicine, University of London, Dr. Nick is a pioneering creator in the evolution of healthcare technology. After several years as a medical practitioner in London and Australia, he joined an international who’s who in healthcare, academia and business, in the development of the first electronic medical record in the early 1990’s and later, as a business leader in one of the first speech recognition Internet companies.
His rare combination of patience, creativity, skill and intrinsic business ethics has led him to a diverse career in healthcare with some of the most prestigious hospitals, consulting firms, and technology companies. He is a member of the HIMSS mHealth Committee where he pays attention not just to processes and systems, but to people. His ability to speak in terms people can actually understand makes him a sought-out speaker on the practical and futuristic use of healthcare technology and how it can cost-effectively improve patient care.
In addition to writing and lecturing on futuristic trends in healthcare technology, his advice and counsel is sought by hospitals, physicians and other allied healthcare professionals — all of whom are trying to figure out how to integrate and use technology to make the healthcare system work from the perspectives of quality and financial success.
Chris Grilli, PharmD.
Manager of Outpatient Pharmacy, Mayo Clinic
Chris received his Doctorate of Pharmacy from Creighton University College of Pharmacy. In addition he is Board Certified in Ambulatory Care Pharmacy through the Board of Pharmacy Specialties. Currently he oversees outpatient pharmacy operations for Mayo Clinic Arizona. He helped found Mayo Clinic Arizona’s Ambulatory Medication Therapy Management Program as well as a Pharmacogenomics program specialty. He is also a founding member of Mayo Clinic’s enterprise wide Pharmacogenomic Round Table.
Chris is a dedicated educator, precepting as often as possible. In collaboration with ASU he is actively researching process improvement and healthcare delivery workflows within Mayo Clinic’s multidisciplinary practice. In addition Chris is tasked with overseeing all pharmacy operations for our Ambulatory Infusion Center located on our Scottsdale campus. He also has developed a full service compounding operation so that patients can have their medications individualized.
With over a decade of experience in pharmacy leadership and practice Chris has been tasked with brining pharmacogenomics from the bench to the bedside.
Michael Misialek, MD.
Associate Chair, Pathology, Newton-Wellesley Hospital
Dr. Misialek currently serves as Associate Chair of Pathology at Newton-Wellesley Hospital, Newton, MA. He is the Medical Director of the Vernon Cancer Center, Chemistry Laboratory and Point of Care Testing. Holding an academic appointment at Tufts University School of Medicine, he regularly instructs medical students and pathology residents. Dr. Misialek is a strong advocate for pathology and is very active in the College of American Pathologists (CAP), serving on the Personalized Healthcare Committee, the Council for Membership and Professional Development, the political action committee PathPAC and the CAP Foundation. He is an inspector with the CAP and has conducted numerous hospital laboratory inspections. He served on the Clinical and Laboratory Standards Institute (CLSI) Document Development Committee on “Reporting Critical, Life-Threatening, or Life-Altering Lab Results” and currently serves on the CLSI Document Development Committee on “Specimen Handling for Molecular Methods”.
He received his MD from the University of Massachusetts, did an internship in internal medicine at Boston Medical Center and completed his residency in anatomic and clinical pathology at the University of Massachusetts Medical Center. He did a fellowship in surgical pathology at the University of Florida and is board certified in Anatomic and Clinical Pathology.
Kaylene Simpson, Ph.D.
Associate Professor & Head Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre
Associate Professor Kaylene Simpson Heads the Victorian Centre for Functional Genomics (VCFG) at Peter MacCallum Cancer Centre. The VCFG enables researchers Australia-wide to perform unbiased gene discovery using high throughput gene targeting approaches such as CRISPR/cas9 and RNA interference, quantitative Reverse Phase Protein Arrays, boutique compound screening and high content imaging. She leads a highly experienced team who actively engage with researchers to help drive their research projects to fruition. Associate Professor Simpson is a molecular cell biologist who specialised in breast cancer invasion and metastasis while a postdoctoral fellow at Harvard Medical School. She has a wealth of experience in assay development, data interpretation and analysis and overall guidance in the area of functional genomics. She is a founding Board member and the current president of the Society of Biomolecular Imaging and Informatics (SBI2).
Thomas P. Conrads, Ph.D.
Thomas P. Conrads, PhD, Associate Director of Scientific Technologies, Inova Schar Cancer Institute
Thomas P. Conrads, PhD, a nationally-recognized translational cancer researcher, serves as the Associate Director of Scientific Technologies in the Inova Schar Cancer Institute. He also serves as the Chief Scientific Officer of the Department of Defense Gynecologic Cancer Center of Excellence and is leading the discovery proteomics efforts in the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) program in the US Federal Cancer Moonshot that is working to obtain detailed proteogenomic profiles on 8000 cancer patients. Dr. Conrads’ scientific career has been spent developing new technologies in chemistry and biology and applying cutting-edge applications and workflows in genomics and proteomics for systems biology and cancer biomarker discovery and validation in tissues, proximal fluids and serum/plasma. The overarching goals of his research are toward identification of genomic, proteomic and small molecule biomarkers and surrogates for enhanced cancer patient management through improved early detection, patient stratification, and monitoring for therapeutic efficacy, outcome and recurrence.
Simon Lovestone, Ph.D.
Professor of Translational Science – University of Oxford Department of Psychiatry
Simon Lovestone is Professor of Translational Neuroscience at Oxford University and has research interests in the regulation of tau phosphorylation, in the search for genetic and other biomarkers of Alzheimer’s disease and building on these, in drug discovery and experimental medicine. Underpinning all these studies is the use of informatics – clinical informatics, bioinformatics and the challenges of extracting value from very large variable datasets. He is also a practicing Old Age Psychiatrist specialising in dementia detection, diagnosis and management. The lab group’s work is described here http://www.psych.ox.ac.uk/research/dementia-research-group and the ARUK Oxford Drug Development Institute led by Lovestone and Bountra is here http://oxford-ddi.alzheimersresearchuk.org/
Jun Wang, Ph.D.
Founder and CEO of iCarbonX
Jun Wang is the Founder and CEO of iCarbonX. He is also Board Member of the BGI (previously known as the Beijing Genomics Institute). He co-founded BGI in the 1999, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. Dr. Wang also holds a position as an Ole Rømer professor at the University of Copenhagen.
He has authored 400+ peer-reviewed original papers – of which 100+ are published in Cell, Nature (including Nature series), N Engl J Med., and Science (26 as cover story). He has been recognized with an award from His Royal Highness Prince Foundation, Nature’s 10 – the year in Science (2012); “Highly Cited Researchers (2013/2014/2015)” “The Hottest Scientific Researchers” (by Thomson Reuters), “Rebels, leaders, innovators for the next 25 years” (by CNBC), “Fortune’s 40 under 40” from Fortune Magazine (2013), Lundbeck Talent Price, Outstanding Science and Technology Achievement from the Chinese Academy of Sciences, Outstanding Technical Talent, ZhouGuangZhao Award, TanJiaZeng Life Science Innovation Award, Top 10 Scientific Achievements In China, Major Award from Shenzhen Municipal Government, and Prize for Important Innovation and Contribution from Chinese Academy of Sciences.
His research focuses on genomics and related bioinformatics analysis of complex diseases and agricultural crops, with the goal of developing applications using the genomic information.
Dr. Wang also managed to have three round fund-raising (about 1B$) at BGI, and acquired a US public company: Complete Genomics. Oct 27th 2015, Dr. Wang founded a new institute/company, iCarbonX, aiming to establish a health-related big Omics data platform, to develop artificial intelligence engine to interpret and mine the data as well as to enable every individual to better manage their health and defeat diseases.
Larry Gold, Ph.D.
Chairman and Founder of Somalogic, Founder of NeXstar and Synergen
Dr. Larry Gold is the Founder and Chairman of the board, and Past CEO of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. Before forming NeXagen, he also co-founded and served as co-director of research at Synergen, Inc., a biotechnology company later acquired by Amgen, Inc.
Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder. While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992. Dr. Gold has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology.
Deepak Asudani, MD, MPH
Associate Clinical Professor of Medicine at University of California, San Diego
Dr. Asudani is an Associate Clinical Professor of Medicine at University of California, San Diego. He graduated with Bachelors in Medicine and Surgery from Rajasthan University, India and went on to complete Internal Medicine residency from New York Medical College, New York. With strong interest in public policy, global health and population health he completed Masters in Public Health from University of Massachusetts, Amherst. An alumni of Harvard Kennedy School of Government Executive education, he is also actively engaged in various leadership roles. He serves as the Medical Director for Hospital Medicine International Patients’ Program and is Chair, Outreach and Clinical Integration. He has been actively engaged with the Practice Management Committee and Public Policy Committee of the Society of Hospital Medicine. This has allowed him to work closely with national thought leaders in public policy development and advocacy. He has a strong interest in applied genomics with particular focus on pharmacogenomics. He believes that modern day genomic sequencing technology delivers a more focused understanding of an individual’s genetic configuration, and in this context – a better pixelated understanding of personalized diagnostics and therapeutics. He will be a regular contributor to the Journal of Precision Medicine’s Clinical Perspective section.
Mark Boguski, MD
Chief Medical Officer of Inspirata, Inc.
Dr. Mark Boguski is the Chief Medical Officer of Inspirata, Inc. and founded the Precision Medicine Network in 2014. He is member of the U.S. National Academy of Medicine and a Fellow of both the College of American Pathologists and the American College of Medical Informatics. Dr. Boguski has served on the faculties of the U.S. National Institutes of Health, the Johns Hopkins University School of Medicine and Harvard Medical School and as an executive in the biotechnology and pharmaceutical industries. He is a former Vice President and Global Head of Genome and Protein Sciences at Novartis and a graduate of the Medical Scientist Training Program at Washington University in St. Louis.
Founder and CEO of Alva10
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Diagnostics are the key to Precision Medicine, but they need to be valued in the healthcare market in order to be successful. For years, diagnostics have been stuck in a downward cycle of value, with poor reimbursement leading to lack of investment, and lack of investment leading to sub-optimal clinical validation, leading back to poor reimbursement. Alva10 is changing that, bringing diagnostics to the forefront of Precision Medicine by partnering with payers and diagnostics companies using a proprietary algorithm to determine economic impact of diagnostics and create a new value based healthcare model.
Alan Sachs, MD, Ph.D.
Chief Scientific Officer for Thermo Fisher Scientific
Dr. Sachs leads efforts to maximize growth through investments in R&D that position the company to help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. He served as the Chief Scientific Officer for Life Technologies and Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge, MA. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, and at Stanford Medical School received his Ph.D. with Roger Kornberg in Cell Biology, his M.D., and performed post-doctoral research with Ron Davis. Dr. Sachs is on the Board of Directors for Imago BioSciences and Advisory Board for Bakar Fellows at University of California, Berkeley.
Dr. Simon Kos, MBBS, BSc, MBA
Chief Medical Officer, Worldwide Health, Microsoft
Dr. Simon Kos joined Microsoft in 2010 to bring health domain expertise to the health team. He brings insight and experience from over 17 years working in the healthcare and Health IT industries. As the doctor on Microsoft’s Worldwide Health team, he is responsible for clinical strategy and industry engagement. He raises awareness of the Microsoft brand, technologies and partner community, and works to find clinical relevance for Microsoft products.
Prior to coming to Microsoft, Dr. Kos worked with global health IT companies Cerner and InterSystems as they implemented some of the largest e-Health initiatives in the Asia-Pacific region. His responsibilities included product design and localisation, clinical engagement, industry thought leadership and team management. Before his career in health IT Dr. Kos practiced as a doctor at NSWHealth, Australia for several years with a focus on critical care.
Dr. Kos has an MBBS and BSc(Med) from UNSW, and an MBA with a major in change management from AGSM. He is passionate about improving healthcare through technology.
Gary Siuzdak, Ph.D.
Professor & Senior Director, The Scripps Research Institute
Gary Siuzdak is Professor and Director of the Scripps Center for Metabolomics at The Scripps Research Institute. He is an affiliate scientist at the Lawrence Berkeley National Lab and has served as Vice President of the American Society for Mass Spectrometry. His research includes developing novel technologies for metabolomics, imaging and system biology. He has over 200 peer-reviewed publications and two books including the “The Expanding Role of Mass Spectrometry in Biotechnology”.
Mary E. Maxon, Ph.D.
Associate Laboratory Director for Biosciences, Lawrence Berkeley National Laboratory
Mary Maxon is the Biosciences Area Principal Deputy at Lawrence Berkeley National Laboratory, where she is responsible for developing strategies for the use of biosciences to address national-scale challenges in energy and environment. She has extensive experience in both the public and private sectors, having served as the Assistant Director for Biological Research at the White House Office of Science and Technology Policy (OSTP) in the Executive Office of the President, where she developed the National Bioeconomy Blueprint, Director of the Marine Microbiology Program at the Gordon and Betty Moore Foundation, and in executive and management roles at Cytokinetics and Microbia, Inc. Maxon received her Ph.D. from the University of California, Berkeley and performed postdoctoral research in biochemistry and genetics at the University of California, San Francisco.
Hans Erik Henriksen
CEO of Healthcare DENMARK
Hans Erik Henriksen is CEO of Healthcare DENMARK. Healthcare DENMARK is a public private partnership organization, with a national mandate to promote Danish healthcare solutions and competencies abroad. The partnership is a framework for linking international partners with efficient Danish solutions and does not represent individual companies. He has a solid healthcare background from different executive positions during the latest 20 years. He was CEO of the innovative Danish healthcare-IT company Cetrea, which during 2008- 2012 was established as a leading provider of solutions to the Danish market and during
the same period accessed markets in other Nordic countries, Germany, Netherlands and USA.
Before joining Cetrea, he was responsible for IBM Healthcare and Life Sciences in the Northern and Eastern part of Europe (the countries U.K., Ireland, South Africa, Germany, Austria, Switzerland, the Nordic Countries and Central and Eastern Europe).
Since 2008 he has also been engaged as board member in a number of different healthcare and healthcare-IT companies. During 2012 he was a member of the Danish Governments Growth team for Healthcare and welfare solutions.
Dr. John Rudan
Professor and Head of Department of Surgery
Britton Smith Chair in Surgery
Dr. Rudan is a Professor and Head of the Department of Surgery at Queen’s University, Kingston Health Sciences Centre. His clinical interest spans across computer-assisted orthopaedic surgery, total joint surgery to oncology. As Director of Clinical Research at the Human Mobility Research Centre (HMRC) and Britton Smith Chair, Dr. Rudan has made significant contributions to patient health and mobility through innovative surgical procedures.
Dr. Rudan is a pioneer in computer-aided research, particularly in Orthopaedics. His effort to integrate this type of surgical platform in the operating theatre has generated over 240 peer-reviewed publications. He also has broad experience in other surgical applications in Neurosurgery, General Surgery and Cardiac Surgery. Currently, in collaboration with the Laboratory for Percutaneous Surgery at Queen’s University, he is leading research in novel navigation for the resection of breast, liver and other soft tissue tumours.
Dr. Rudan is a named inventor on 23 patent applications and 25 patents worldwide, many of which have been licensed to Fortune 500 companies.
Patient Advocate at Inspire2Live
As a Patient Advocate of Inspire2Live Peter connects patients, researchers and clinicians to further research, treatments and care; in the Netherlands as well as international. He organizes congresses, lobbies the matrix of public authorities, health care organizations, insurance companies and health research institutes. Peter also gives lectures and talks to help patients and society to fight cancer where possible and live with cancer with a good quality of life. He writes blogs, articles and books that contribute to these topics. Peter shows people their shining and radiant possibilities in every possible situation and lets them exploit their talents in favour of others. He’s creating Awareness and Hope where hope comes through vision.
Peter is the co-founder of Alpe d’HuZes, the foundation that is most famous for the annual cycling event on Mount Alpe d’Huez and that raised over 125 million euro for the fight against cancer. He works at the Central Bank of the Netherlands as a program manager and advisor for complex and politically difficult problems. His employer facilitates him in this job. Peter was honoured with a doctorate in October 2012 at the Free University in Amsterdam for connecting patients, researchers and clinicians all over the world to contribute to the quality of life of patients and their loved ones.
Dr. Thomas Wilckens
CEO InnVentis Ltd.
Thomas Wilckens is an MD and serial entrepreneur. His current focus is venture InnVentis Ltd (Israel) and the convergence of multi-omics technologies with real-world clinical data and machine learning to enable PRECISION MEDICINE, Thomas is also the founder of the LinkedIn group PRECISION MEDICINE Insight an Associate at deep innovation GmbH, a boutique consultancy headed by the fmr. Head Group R&D Vodafone. Before joining deep innovation, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University before heading off to basic research as a scholar of the Max-Planck Society and the Max-Kade Foundation, NY. He held several postdoc positions at leading academic institutions before becoming an entrepreneur. Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas is an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.
Yves A. Lussier, MD, FACMI
Associate Vice President for Data Science, The University of Arizona Health Sciences, Director, Center for Biomedical Informatics and Biostatistics
Dr. Lussier is the Associate Vice President for Data Science and Chief Knowledge Officer for The University of Arizona Health Sciences. He also currently serves as the Director of the Center for Biomedical Informatics and Biostatistics, Associate Director for Cancer Informatics and Precision Health, and the Associate Director for Informatics of the BIO5 Institute at The University of Arizona. He is an internationally renowned physician-scientist and a pioneer of the field of translational bioinformatics. A practitioner of medicine for over seventeen years, he has been a member of the administrative board of four hospitals and published over 150 scientific papers and books chapters. He previously served as Director of three NIH-Funded bioinformatics cores at Columbia University and the University of Chicago. Dr. Lussier co-founded Purkinje, the first tablet-based electronic medical records anchored on the first commercial ontology, as well as developed and implemented Vigilens, the first ontology-anchored clinical event monitor that has been in operation at the New York Presbyterian Hospital of Columbia University since 2002. Leveraging bio-ontologies, he has pioneered and enabled clinical interpretation of personal transcriptomes dynamics between two samples, thus abrogating cohort-based statistics requirements
Dr. Lussier strongly believes that since every patient is a unique individual with a wide range of variability in genes, environment, and lifestyle, it is necessary to devise custom strategies when designing treatment methods. In his role as the Director of the Center for Biomedical Informatics and Biostatistics (CB2), he leads the initiative to build a data-driven learning health system, advance precision medicine analytics, and translate Big Data science and genomic discoveries to clinical care for The University of Arizona’s research and clinical communities. In addition to his role with CB2, his research group conducts hypothesis-driven translational research in biomedical informatics using clinical and genomic big data, knowledge technologies, and networks to better understand the pathology, progression, and treatment for diseases at the individual patient level. They are developing scalable computational data science technologies to efficiently and affordably heal humanity – one person at a time.
Lynn G. Dressler, Dr.P.H.
Director of Personalized Medicine, Fullerton Genetics Center and Mission SECU Cancer Center, Mission Health.
Dr. Dressler joined Mission Health, in February 2013, to develop and direct the Personalized Medicine and Pharmacogenomics Program. Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of the UNC Institute for Pharmacogenomics and Individualized Therapy, Dressler’s 30 year career spans translational laboratory research in cancer, health policy research and the ethical ,legal, and social implications (ELSI) of genomic medicine. Dressler holds a Master’s in Experimental Pathology, a doctorate in Health Policy and completed a fellowship in ELSI research. At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion ™), one of the first pharmacogenomic tests in solid tumors. In North Carolina, nearly 10 years prior to GINA, (Genetic Information Non Discrimination Act, Federal Statute), Dressler worked with the North Carolina General Assembly to pass a law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information. She has over 100 publications in related fields.
Working closely with NIH/NCI/NHGRI, Dressler has served in many leadership roles (External Advisor to The Cancer Genome Atlas Study (TCGA); NCI caHUB ethics working group, co- Chair Correlative Sciences Committee of the Cancer and Leukemia Group B). She currently serves as a member of the Clinical Pharmacogenomics Implementation Committee (CPIC); an affiliate member of the NIH Consortium IGNITE, and a guest member of the Institute of Medicine’s Roundtable on Translating Genomic Findings to Improve Population Health.
Dr. Paul R. Billings, M.D., Ph.D, FACP, FACMG
Co-Founder, CMO of Fabric Genomics
Dr. Paul R. Billings is a board-certified internist and clinical geneticist. He is a Principal in the consultancy, the Bethesda Group and is Chairman of both PlumCare, LLc and Biological Dynamics, Inc. Dr. Billings has held appointments at Harvard University, UCSF, Stanford University and UCB. He is a co-founder and CMO of Fabric Genomics
Atul Butte, MD, PhD
Director of the Institute of Computational Health Sciences
Atul Butte, MD, PhD is the inaugural Director of the Institute of Computational Health Sciences (ichs.ucsf.edu) at the University of California, San Francisco, and a Distinguished Professor of Pediatrics. Dr. Butte is also the Executive Director for Clinical Informatics across the six University of California Medical Schools and Medical Centers. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD from Harvard Medical School and MIT. Dr. Butte has authored nearly 200 publications, with research repeatedly featured in Wired Magazine, the New York Times, and the Wall Street Journal. Dr. Butte was elected into the National Academy of Medicine in 2015, and in 2013, he was recognized by the White House as an Open Science Champion of Change for promoting science through publicly available data. Dr. Butte is also a founder of three investor-backed data-driven companies: Personalis, providing clinical interpretation of whole genome sequences, Carmenta (acquired by Progenity), discovering diagnostics for pregnancy complications, and NuMedii, finding new uses for drugs through open molecular data. Dr. Butte is a principal investigator of three major programs: the California Initiative to Advance Precision Medicine; the California Precision Medicine Consortium, helping recruit tens of thousands of participants into President Obama’s Precision Medicine Initiative; and ImmPort, the clinical and molecular data repository for the National Institute of Allergy and Infectious Diseases.
James N. Czaban
Partner & Chairman of the FDA and Medical Products Regulatory Practice Group at DLA Piper LLP
James N. Czaban is a Partner and the Chairman of the FDA and Medical Products Regulatory Practice Group at the international law firm DLA Piper LLP, in Washington, D.C. In nearly 25 years of private practice, Jim has focused on counseling pharmaceutical, medical device and diagnostic, and other life sciences clients on a broad range of complex regulatory strategies and compliance matters, and regularly represents such clients in legal, public policy, and enforcement matters before the FDA, other administrative agencies, and in the federal courts. Jim has been deeply involved in the law and regulation of Precision Medicine since mapping of the human genome was completed more than 15 years ago. In 2001, Mr. Czaban published one of the first scholarly legal analyses of FDA’s potential approaches to regulating Precision Medicine, titled “Pharmacogenomics: The Uncertain Path to Deciphering the Regulatory Genome,” and more recently, published a comprehensive analysis of FDA’s efforts to tighten its control over the development and commercialization of Precision Medicine technologies, in the article “Promotion of Precision Medicine Under Imprecise Rules” (FDLI 2016). Mr. Czaban is a recipient of the Burton Award for Legal Excellence (2010) for his groundbreaking work involving FDA regulation of, and patent litigation involving, the emerging field of biosimilar products. He earned his undergraduate degree from the University of California, Berkeley (1988), and his law degree from the University of Virginia School of Law (1992).
Emanuel Petricoin III, PhD
University Professor, Co-Director Center for Applied Proteomics and Molecular Medicine, George Mason University
Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery. He is a co-founder of 4 life science companies, including 2 precision medicine companies: Theranostics Health, Inc. and Perthera, Inc. located in McClean VA, where is a co-founder and Chief Science Officer. He is a co-inventor on 40 filed and published patents, and has authored over 360 peer-reviewed publications and invited reviews. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is s Kentucky Colonel. He is the faculty representative to the George Mason University Research Foundation.
Dr. George Poste
Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University
Dr. Poste is currently the Professor of Health Innovation and Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University. This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine.
He serves on the Board of Directors of Monsanto, Exelixis, Caris Life Sciences and Scientific Advisory Boards at the University of Michigan, Synthetic Genomics and Haplogen GmbH.
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and U.K. Academy of Medicine, Member, Council for Foreign Relations, and Institute of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.
Lee S. Schwartzberg, M.D., F.A.C.P.
Executive Director and Chief Medical Officer, the West Cancer Center
Lee S. Schwartzberg, M.D., F.A.C.P. is the Executive Director and chief medical officer of the West Cancer Center. He is a Professor of Medicine and Chief, Division of Hematology/Oncology at The University of Tennessee Health Science Center. Dr. Schwartzberg is board certified in internal medicine, hematology, and medical oncology. He also serves as President /CMO for Vector Oncology, an oncology specific SMO/CRO. He was the founding editor-in-chief of the journal Community Oncology and serves as the editor-in-chief of the website Practice Update Oncology. He serves on the editorial board of the Journal of Supportive Oncology and the ASCO post and is a reviewer for many journals including the New England Journal of Medicine and the Journal of Clinical Oncology. He also serves on the board of directors for the National Comprehensive Cancer Network. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer, targeted therapy and supportive care having published over 150 research papers. He maintains a private practice in medical oncology focusing on breast cancer.
Paul Langley, PhD
Adjunct Professor, College of Pharmacy, University of Minnesota, Director, Maimon Research LLC
Dr Langley is a health economist with over 30 years’ experience in consulting, academia and the pharmaceutical industry. The focus of Dr Langley’s academic and consulting activities is on the evidence base to support clinical and formulary decisions. Over the past 15 years Dr Langley has advised health care systems in the US, Australia and the European Union on the need for processes to be put in place to ensure that claims made for products and devices, both clinical and cost-effective, meet the standards of normal science for evaluation and replication. Dr Langley has published widely and at present is directing a program at the University of Minnesota on formulary evaluation with particular emphasis on personalized and precision medicine claims. The critical feature is the presence of an interactive evidence base that supports at risk target populations in the long-term.